WO2022139552A1 - 단장증후군의 예방 또는 치료를 위한 인슐린 분비 펩타이드 및 glp-2의 병용 요법 - Google Patents
단장증후군의 예방 또는 치료를 위한 인슐린 분비 펩타이드 및 glp-2의 병용 요법 Download PDFInfo
- Publication number
- WO2022139552A1 WO2022139552A1 PCT/KR2021/019854 KR2021019854W WO2022139552A1 WO 2022139552 A1 WO2022139552 A1 WO 2022139552A1 KR 2021019854 W KR2021019854 W KR 2021019854W WO 2022139552 A1 WO2022139552 A1 WO 2022139552A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- glp
- insulin
- derivative
- pharmaceutical composition
- exendin
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 180
- 206010049416 Short-bowel syndrome Diseases 0.000 title claims abstract description 66
- 238000002648 combination therapy Methods 0.000 title abstract description 4
- 230000002473 insulinotropic effect Effects 0.000 title abstract 2
- TWSALRJGPBVBQU-PKQQPRCHSA-N glucagon-like peptide 2 Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(O)=O)[C@@H](C)CC)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=CC=C1 TWSALRJGPBVBQU-PKQQPRCHSA-N 0.000 claims abstract description 261
- 101800000221 Glucagon-like peptide 2 Proteins 0.000 claims abstract description 185
- 102400000326 Glucagon-like peptide 2 Human genes 0.000 claims abstract 12
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 295
- 102000004877 Insulin Human genes 0.000 claims description 147
- 108090001061 Insulin Proteins 0.000 claims description 147
- 229940125396 insulin Drugs 0.000 claims description 147
- 230000003248 secreting effect Effects 0.000 claims description 145
- 150000001413 amino acids Chemical class 0.000 claims description 124
- 235000001014 amino acid Nutrition 0.000 claims description 83
- 239000000203 mixture Substances 0.000 claims description 77
- 239000008194 pharmaceutical composition Substances 0.000 claims description 75
- 108060003951 Immunoglobulin Proteins 0.000 claims description 64
- 102000018358 immunoglobulin Human genes 0.000 claims description 64
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 63
- 239000004472 Lysine Substances 0.000 claims description 52
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 52
- JUFFVKRROAPVBI-PVOYSMBESA-N chembl1210015 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N[C@H]1[C@@H]([C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@]3(O[C@@H](C[C@H](O)[C@H](O)CO)[C@H](NC(C)=O)[C@@H](O)C3)C(O)=O)O2)O)[C@@H](CO)O1)NC(C)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 JUFFVKRROAPVBI-PVOYSMBESA-N 0.000 claims description 52
- 125000003277 amino group Chemical group 0.000 claims description 50
- 229960001519 exenatide Drugs 0.000 claims description 48
- 238000011282 treatment Methods 0.000 claims description 38
- 108010011459 Exenatide Proteins 0.000 claims description 36
- 235000018417 cysteine Nutrition 0.000 claims description 34
- 238000001727 in vivo Methods 0.000 claims description 33
- 230000002265 prevention Effects 0.000 claims description 33
- 239000004471 Glycine Substances 0.000 claims description 30
- 229920001223 polyethylene glycol Polymers 0.000 claims description 30
- 239000000126 substance Substances 0.000 claims description 30
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 29
- 239000004475 Arginine Substances 0.000 claims description 28
- 239000002202 Polyethylene glycol Substances 0.000 claims description 28
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 28
- 238000000034 method Methods 0.000 claims description 28
- FUOOLUPWFVMBKG-UHFFFAOYSA-N 2-Aminoisobutyric acid Chemical compound CC(C)(N)C(O)=O FUOOLUPWFVMBKG-UHFFFAOYSA-N 0.000 claims description 27
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical group OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 27
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 24
- 210000000813 small intestine Anatomy 0.000 claims description 24
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 22
- 230000004048 modification Effects 0.000 claims description 22
- 238000012986 modification Methods 0.000 claims description 22
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 20
- 229910052799 carbon Inorganic materials 0.000 claims description 20
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 18
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 claims description 17
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 15
- 238000006467 substitution reaction Methods 0.000 claims description 15
- 235000004279 alanine Nutrition 0.000 claims description 14
- 229920001184 polypeptide Polymers 0.000 claims description 14
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 13
- 239000000560 biocompatible material Substances 0.000 claims description 13
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 13
- QFLNJOIJUNDRFH-ROLXFIACSA-N [(5s)-1,5-diamino-5-carboxypentyl]-diazonioazanide Chemical compound [N-]=[N+]=NC(N)CCC[C@H](N)C(O)=O QFLNJOIJUNDRFH-ROLXFIACSA-N 0.000 claims description 11
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 10
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 10
- 238000007792 addition Methods 0.000 claims description 9
- ZCKYOWGFRHAZIQ-UHFFFAOYSA-N dihydrourocanic acid Chemical compound OC(=O)CCC1=CNC=N1 ZCKYOWGFRHAZIQ-UHFFFAOYSA-N 0.000 claims description 9
- 239000000539 dimer Substances 0.000 claims description 9
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 9
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 9
- IMOBSLOLPCWZKQ-UHFFFAOYSA-N 2-(dimethylazaniumyl)-3-(1h-imidazol-5-yl)propanoate Chemical compound CN(C)C(C(O)=O)CC1=CN=CN1 IMOBSLOLPCWZKQ-UHFFFAOYSA-N 0.000 claims description 8
- 230000037430 deletion Effects 0.000 claims description 8
- 238000012217 deletion Methods 0.000 claims description 8
- LMHMJYMCGJNXRS-IOPUOMRJSA-N exendin-3 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@H](C)O)[C@H](C)O)C(C)C)C1=CC=CC=C1 LMHMJYMCGJNXRS-IOPUOMRJSA-N 0.000 claims description 8
- 230000005176 gastrointestinal motility Effects 0.000 claims description 8
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims description 8
- 230000007423 decrease Effects 0.000 claims description 7
- 108010015174 exendin 3 Proteins 0.000 claims description 7
- 239000012634 fragment Substances 0.000 claims description 7
- 230000002441 reversible effect Effects 0.000 claims description 7
- 239000000556 agonist Substances 0.000 claims description 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 6
- 235000015816 nutrient absorption Nutrition 0.000 claims description 6
- 239000003085 diluting agent Substances 0.000 claims description 5
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 4
- GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical group C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 claims description 4
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 claims description 3
- 230000004584 weight gain Effects 0.000 claims description 3
- 235000019786 weight gain Nutrition 0.000 claims description 3
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 claims description 2
- 102100040918 Pro-glucagon Human genes 0.000 description 184
- 239000000562 conjugate Substances 0.000 description 112
- 229940024606 amino acid Drugs 0.000 description 76
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 38
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 35
- 230000006872 improvement Effects 0.000 description 24
- 229920000642 polymer Polymers 0.000 description 19
- 238000006243 chemical reaction Methods 0.000 description 16
- -1 derivatives Substances 0.000 description 16
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 14
- 238000002360 preparation method Methods 0.000 description 14
- 101800000224 Glucagon-like peptide 1 Proteins 0.000 description 11
- 241000699670 Mus sp. Species 0.000 description 11
- 125000000539 amino acid group Chemical group 0.000 description 11
- 239000003814 drug Substances 0.000 description 11
- 125000003396 thiol group Chemical group [H]S* 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 235000013305 food Nutrition 0.000 description 10
- 230000006870 function Effects 0.000 description 10
- 238000007069 methylation reaction Methods 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 125000003172 aldehyde group Chemical group 0.000 description 8
- 210000004899 c-terminal region Anatomy 0.000 description 8
- 238000011260 co-administration Methods 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 235000000346 sugar Nutrition 0.000 description 8
- IVRMZWNICZWHMI-UHFFFAOYSA-N azide group Chemical group [N-]=[N+]=[N-] IVRMZWNICZWHMI-UHFFFAOYSA-N 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 239000000710 homodimer Substances 0.000 description 7
- 239000000178 monomer Substances 0.000 description 7
- 229910052757 nitrogen Inorganic materials 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 150000003839 salts Chemical class 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 230000009471 action Effects 0.000 description 6
- 125000000524 functional group Chemical group 0.000 description 6
- 230000036541 health Effects 0.000 description 6
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical class O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 6
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 5
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 5
- 125000003412 L-alanyl group Chemical group [H]N([H])[C@@](C([H])([H])[H])(C(=O)[*])[H] 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 230000009615 deamination Effects 0.000 description 5
- 238000006481 deamination reaction Methods 0.000 description 5
- 125000004433 nitrogen atom Chemical group N* 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 description 4
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 4
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 4
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 4
- 108091005804 Peptidases Proteins 0.000 description 4
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 4
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 4
- NBBJYMSMWIIQGU-UHFFFAOYSA-N Propionic aldehyde Chemical group CCC=O NBBJYMSMWIIQGU-UHFFFAOYSA-N 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 150000001294 alanine derivatives Chemical class 0.000 description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 239000003610 charcoal Substances 0.000 description 4
- 230000000875 corresponding effect Effects 0.000 description 4
- 238000005805 hydroxylation reaction Methods 0.000 description 4
- 230000003914 insulin secretion Effects 0.000 description 4
- 125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 235000012054 meals Nutrition 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 239000000863 peptide conjugate Substances 0.000 description 4
- 125000001151 peptidyl group Chemical group 0.000 description 4
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 4
- 230000004580 weight loss Effects 0.000 description 4
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 102000009027 Albumins Human genes 0.000 description 3
- 108010088751 Albumins Proteins 0.000 description 3
- ZTQSAGDEMFDKMZ-UHFFFAOYSA-N Butyraldehyde Chemical group CCCC=O ZTQSAGDEMFDKMZ-UHFFFAOYSA-N 0.000 description 3
- 229920002307 Dextran Polymers 0.000 description 3
- 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 description 3
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 description 3
- 101800004266 Glucagon-like peptide 1(7-37) Proteins 0.000 description 3
- 239000007995 HEPES buffer Substances 0.000 description 3
- 125000000570 L-alpha-aspartyl group Chemical group [H]OC(=O)C([H])([H])[C@]([H])(N([H])[H])C(*)=O 0.000 description 3
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 3
- 206010025476 Malabsorption Diseases 0.000 description 3
- 208000004155 Malabsorption Syndromes Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 102000035195 Peptidases Human genes 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000003638 chemical reducing agent Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000004540 complement-dependent cytotoxicity Effects 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 3
- 230000001766 physiological effect Effects 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000002335 preservative effect Effects 0.000 description 3
- 238000006268 reductive amination reaction Methods 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000001509 sodium citrate Substances 0.000 description 3
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 229910052717 sulfur Inorganic materials 0.000 description 3
- 125000004434 sulfur atom Chemical group 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 238000011740 C57BL/6 mouse Methods 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 241000700198 Cavia Species 0.000 description 2
- 229920002101 Chitin Polymers 0.000 description 2
- 241000699800 Cricetinae Species 0.000 description 2
- 208000005156 Dehydration Diseases 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 108010014258 Elastin Proteins 0.000 description 2
- 102000016942 Elastin Human genes 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 102000051325 Glucagon Human genes 0.000 description 2
- 108060003199 Glucagon Proteins 0.000 description 2
- 102000015626 Glucagon-Like Peptide-2 Receptor Human genes 0.000 description 2
- 108010024044 Glucagon-Like Peptide-2 Receptor Proteins 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- 125000003440 L-leucyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C(C([H])([H])[H])([H])C([H])([H])[H] 0.000 description 2
- 125000002842 L-seryl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])O[H] 0.000 description 2
- 201000010538 Lactose Intolerance Diseases 0.000 description 2
- 206010024264 Lethargy Diseases 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 108090000526 Papain Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- RFBKULCUBJAQFT-BIIVOSGPSA-N Ser-Cys-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CS)NC(=O)[C@H](CO)N)C(=O)O RFBKULCUBJAQFT-BIIVOSGPSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 230000009435 amidation Effects 0.000 description 2
- 238000007112 amidation reaction Methods 0.000 description 2
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 238000011888 autopsy Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 229920002988 biodegradable polymer Polymers 0.000 description 2
- 239000004621 biodegradable polymer Substances 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000018044 dehydration Effects 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 230000006806 disease prevention Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 201000006549 dyspepsia Diseases 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 229920002549 elastin Polymers 0.000 description 2
- FJKIXWOMBXYWOQ-UHFFFAOYSA-N ethenoxyethane Chemical compound CCOC=C FJKIXWOMBXYWOQ-UHFFFAOYSA-N 0.000 description 2
- 206010016256 fatigue Diseases 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000012847 fine chemical Substances 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 235000013376 functional food Nutrition 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 2
- 229960004666 glucagon Drugs 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 229920001519 homopolymer Polymers 0.000 description 2
- 229920002674 hyaluronan Polymers 0.000 description 2
- 229960003160 hyaluronic acid Drugs 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 230000011987 methylation Effects 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 125000004430 oxygen atom Chemical group O* 0.000 description 2
- 229940055729 papain Drugs 0.000 description 2
- 235000019834 papain Nutrition 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 230000002688 persistence Effects 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229920001583 poly(oxyethylated polyols) Polymers 0.000 description 2
- 229920001451 polypropylene glycol Polymers 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 239000001103 potassium chloride Substances 0.000 description 2
- 235000011164 potassium chloride Nutrition 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000006722 reduction reaction Methods 0.000 description 2
- 238000005932 reductive alkylation reaction Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 208000001162 steatorrhea Diseases 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 208000016261 weight loss Diseases 0.000 description 2
- DKXIKPOYTWCGIE-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 2-methylbutanoate Chemical compound CCC(C)C(=O)ON1C(=O)CCC1=O DKXIKPOYTWCGIE-UHFFFAOYSA-N 0.000 description 1
- FHNMAOLQZHUPIJ-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 2-methylpropanoate Chemical compound CC(C)C(=O)ON1C(=O)CCC1=O FHNMAOLQZHUPIJ-UHFFFAOYSA-N 0.000 description 1
- DYMYLBQTHCJHOQ-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) butanoate Chemical compound CCCC(=O)ON1C(=O)CCC1=O DYMYLBQTHCJHOQ-UHFFFAOYSA-N 0.000 description 1
- ZJIFDEVVTPEXDL-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) hydrogen carbonate Chemical compound OC(=O)ON1C(=O)CCC1=O ZJIFDEVVTPEXDL-UHFFFAOYSA-N 0.000 description 1
- DRLIANXPAARUMI-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) pentanoate Chemical compound CCCCC(=O)ON1C(=O)CCC1=O DRLIANXPAARUMI-UHFFFAOYSA-N 0.000 description 1
- AASBXERNXVFUEJ-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) propanoate Chemical compound CCC(=O)ON1C(=O)CCC1=O AASBXERNXVFUEJ-UHFFFAOYSA-N 0.000 description 1
- HTFFMYRVHHNNBE-YFKPBYRVSA-N (2s)-2-amino-6-azidohexanoic acid Chemical compound OC(=O)[C@@H](N)CCCCN=[N+]=[N-] HTFFMYRVHHNNBE-YFKPBYRVSA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- 125000001431 2-aminoisobutyric acid group Chemical group [#6]C([#6])(N*)C(*)=O 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- OBMZMSLWNNWEJA-XNCRXQDQSA-N C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 Chemical compound C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 OBMZMSLWNNWEJA-XNCRXQDQSA-N 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- HTQBXNHDCUEHJF-XWLPCZSASA-N Exenatide Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 HTQBXNHDCUEHJF-XWLPCZSASA-N 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 102400000322 Glucagon-like peptide 1 Human genes 0.000 description 1
- 102400000324 Glucagon-like peptide 1(7-37) Human genes 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 101000851054 Homo sapiens Elastin Proteins 0.000 description 1
- 101000886868 Homo sapiens Gastric inhibitory polypeptide Proteins 0.000 description 1
- 101500028771 Homo sapiens Glucagon-like peptide 2 Proteins 0.000 description 1
- 101001015549 Homo sapiens Glucagon-like peptide 2 receptor Proteins 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 1
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- 125000001176 L-lysyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C([H])([H])C([H])([H])C([H])([H])C(N([H])[H])([H])[H] 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 description 1
- 125000000769 L-threonyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])[C@](O[H])(C([H])([H])[H])[H] 0.000 description 1
- 125000003580 L-valyl group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(C([H])([H])[H])(C([H])([H])[H])[H] 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- 125000000729 N-terminal amino-acid group Chemical group 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 101710176384 Peptide 1 Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 229940122985 Peptide agonist Drugs 0.000 description 1
- 229920000805 Polyaspartic acid Polymers 0.000 description 1
- 108010020346 Polyglutamic Acid Proteins 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102000035554 Proglucagon Human genes 0.000 description 1
- 108010058003 Proglucagon Proteins 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical compound CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000005349 anion exchange Methods 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000002744 anti-aggregatory effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 102000023732 binding proteins Human genes 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- WDRMVIMVHHWVBI-STCSGHEYSA-N chembl1222074 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)N[C@@H](CC=1NC=NC=1)C(O)=O)[C@@H](C)O)[C@H](C)O)C(C)C)C1=CC=CC=C1 WDRMVIMVHHWVBI-STCSGHEYSA-N 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 210000001100 crypt cell Anatomy 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000022811 deglycosylation Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000001842 enterocyte Anatomy 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 230000006126 farnesylation Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 230000027119 gastric acid secretion Effects 0.000 description 1
- 230000030136 gastric emptying Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000003877 glucagon like peptide 1 receptor agonist Substances 0.000 description 1
- 230000004190 glucose uptake Effects 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 150000002332 glycine derivatives Chemical class 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 102000044683 human GLP2R Human genes 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000003870 intestinal permeability Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 210000004498 neuroglial cell Anatomy 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 125000000962 organic group Chemical group 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 230000006320 pegylation Effects 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 108010064470 polyaspartate Proteins 0.000 description 1
- 229920002643 polyglutamic acid Polymers 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 239000008057 potassium phosphate buffer Substances 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- UQDJGEHQDNVPGU-UHFFFAOYSA-N serine phosphoethanolamine Chemical compound [NH3+]CCOP([O-])(=O)OCC([NH3+])C([O-])=O UQDJGEHQDNVPGU-UHFFFAOYSA-N 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000019635 sulfation Effects 0.000 description 1
- 238000005670 sulfation reaction Methods 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 230000034512 ubiquitination Effects 0.000 description 1
- 238000010798 ubiquitination Methods 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Definitions
- the present invention relates to a combination therapy of an insulin-secreting peptide and GLP-2 for the prevention or treatment of short bowel syndrome.
- Short bowel syndrome is a dyspepsia caused by the congenital shortness of the small intestine or the loss of more than a certain percentage of the small intestine (reduction of the absorption area of the small intestine) acquired through surgery. , malabsorption, abdominal pain, diarrhea, fatty stool, lactose intolerance, dehydration, weight loss, lethargy, fatigue, etc. may appear.
- Glucagon-like peptide-2 (GLP-2) is a peptide hormone composed of 33 amino acids produced by L-cells in the small intestine in response to ingested nutrients. GLP-2 induces mucosal growth in the small intestine and large intestine, promotes growth of enterocytes and crypt cells, and inhibits apoptosis. GLP-2 also increases the absorption of nutrients from the small intestine and decreases intestinal permeability. It inhibits gastric emptying and gastric acid secretion, increases intestinal blood flow rate, and relaxes intestinal smooth muscle.
- GLP-2 enhances nutrient absorption and gastrointestinal absorption in a rodent experimental model with short bowel syndrome (Ljungmann K et al., Am. J. Physiol. Gastrointest Liver Physiol., 2001, 281(3): G779-85).
- GLP-1 glucagon-like peptide 1
- Exendin-4 a GLP-1 analogue purified from the salivary glands of the glia monster.
- DPP-IV dipeptidyl peptidase-4
- One object of the present invention is to provide a therapy for the prevention, improvement or treatment of short bowel syndrome using an insulin-secreting peptide and GLP-2 (Glucagon-like peptide-2, GLP-2) in combination.
- GLP-2 Glucagon-like peptide-2, GLP-2
- Another object of the present invention is to provide a pharmaceutical composition for the prevention or treatment of short bowel syndrome containing an insulin-secreting peptide, wherein the pharmaceutical composition is administered in combination with GLP-2. .
- Another object of the present invention is to provide a pharmaceutical composition for preventing or treating short bowel syndrome containing GLP-2, wherein the pharmaceutical composition is administered in combination with an insulin-secreting peptide. .
- Another object of the present invention is to provide a combination comprising an insulin secreting peptide and GLP-2.
- Another object of the present invention is to provide a pharmaceutical composition for the prevention, improvement or treatment of short bowel syndrome, comprising the combination.
- Another object of the present invention is to provide a pharmaceutical kit for the prevention, improvement or treatment of short bowel syndrome, comprising an insulin-secreting peptide and GLP-2.
- Another object of the present invention is to provide a method for preventing, improving or treating short bowel syndrome, comprising administering and/or using the combination, pharmaceutical composition, or pharmaceutical kit to an individual in need thereof will be.
- Another object of the present invention includes the steps of co-administering and/or using a composition containing a pharmaceutically effective amount of an insulin-secreting peptide and a composition containing a pharmaceutically effective amount of GLP-2 to an individual in need thereof It is to provide a method for preventing, improving or treating short bowel syndrome.
- Another object of the present invention is the use of the combination, pharmaceutical composition, or pharmaceutical kit for the prevention, improvement or treatment of short bowel syndrome, and/or use for the manufacture of a medicament for the prevention, improvement or treatment of short bowel syndrome. is to provide
- One aspect embodying the present invention is a therapy for the prevention, improvement or treatment of short bowel syndrome using an insulin-secreting peptide and GLP-2 in combination.
- One embodiment embodying the present invention is a composition for the prevention, improvement or treatment of short bowel syndrome containing an insulin-secreting peptide, wherein the insulin-secreting peptide is administered in combination with GLP-2.
- the present invention provides a pharmaceutical composition for the prevention, improvement or treatment of short bowel syndrome containing a pharmaceutically effective amount of an insulin-secreting peptide, wherein the pharmaceutical composition is administered in combination with GLP-2. .
- the present invention provides a food composition for preventing or improving short bowel syndrome containing an insulin-secreting peptide, wherein the food composition is administered in combination with GLP-2.
- One embodiment embodying the present invention is a composition for the prevention, improvement or treatment of short bowel syndrome containing GLP-2, wherein the GLP-2 is administered in combination with an insulin-secreting peptide.
- the present invention provides a pharmaceutical composition for the prevention, improvement or treatment of short bowel syndrome containing a pharmaceutically effective amount of GLP-2, wherein the pharmaceutical composition is administered in combination with an insulin-secreting peptide. .
- the present invention provides a food composition for preventing or improving short bowel syndrome containing GLP-2, wherein the food composition is administered in combination with an insulin-secreting peptide.
- composition according to any one of the preceding embodiments, wherein the insulin-secreting peptide is glucagon-like peptide-1 (GLP-1), exendin-3, exendin-4, or an agonist thereof. , derivatives, fragments, variants, and combinations thereof.
- GLP-1 glucagon-like peptide-1
- exendin-3 exendin-4
- exendin-4 or an agonist thereof.
- derivatives, fragments, variants, and combinations thereof derivatives, fragments, variants, and combinations thereof.
- composition according to any one of the preceding embodiments wherein, in the insulin-secreting peptide, the N-terminal histidine residue of the insulin-secreting peptide is imidazoacetyldeshistidine, desaminohistidine, ⁇ -hydroxyimidazopropionyldeshistidine, N-dimethyl It is characterized as an insulin-secreting peptide derivative substituted with histidine or ⁇ -carboxyimidazopropionyldeshistidine.
- exendin-4 derivative from which is removed exendin-4 derivative from which the N-terminal amino group of exendin-4 has been removed, exendin-4 derivative from which the N-terminal amino group of exendin-4 is substituted with a hydroxyl group
- composition according to any one of the preceding embodiments, wherein the GLP-2 is a native GLP-2 or a GLP-2 derivative.
- composition according to any one of the preceding embodiments, wherein the GLP-2 derivative includes substitution, addition, deletion, modification, and modification of at least one amino acid in the native GLP-2 sequence It is characterized in that it is a GLP-2 derivative with a modification selected from the group consisting of a combination of
- composition according to any one of the preceding embodiments, wherein the GLP-2 derivative is characterized in that at least one amino acid among amino acids 1, 2, 30 and 33 in SEQ ID NO: 1 is modified. .
- composition according to any one of the preceding embodiments, wherein the GLP-2 derivative comprises an amino acid sequence represented by the following general formula 1:
- X 1 is histidine, imidazoacetyldeshistidine, desaminohistidine, ⁇ -hydroxyimidazopropionyldeshistidine, N -dimethylhistidine, or ⁇ -carboxyimidazopropionyldeshistidine;
- X 2 is alanine, glycine, or Aib (2-aminoisobutyric acid);
- X 30 is lysine or arginine
- X 34 is absent or is lysine, arginine, glutamine, histidine, 6-azidolysine or cysteine;
- composition according to any one of the preceding embodiments, wherein the GLP-2 derivative comprises
- X 1 is imidazoacetyldeshistidine
- X 2 is glycine
- X 30 is lysine
- X 34 is cysteine
- X 1 is imidazoacetyldeshistidine
- X 2 is glycine
- X 30 is lysine
- X 34 is lysine
- X 1 is imidazoacetyldeshistidine
- X 2 is glycine
- X 30 is arginine
- X 34 is lysine
- X 1 is imidazoacetyldeshistidine
- X 2 is glycine
- X 30 is lysine
- X 34 is 6-azidolysine
- X 1 is imidazoacetyldeshistidine
- X 2 is glycine
- X 30 is arginine
- X 34 is cysteine
- X 1 is imidazoacetyldeshistidine
- X 2 is Aib
- X 30 is lysine
- X 34 is cysteine
- X 1 is histidine
- X 2 is Aib
- X 30 is lysine
- X 34 is cysteine.
- composition according to any one of the preceding embodiments, wherein the GLP-2 derivative comprises an amino acid sequence represented by the following general formula 2:
- X 1 is histidine, imidazoacetyldeshistidine, desaminohistidine, ⁇ -hydroxyimidazopropionyldeshistidine, N -dimethylhistidine, or ⁇ -carboxyimidazopropionyldeshistidine;
- X 2 is alanine, glycine, or Aib (2-aminoisobutyric acid);
- X 30 is lysine or arginine
- X 34 is one or more optional amino acids or one or more optional amino acids to which a modification has occurred;
- composition when administered to a subject, is characterized in that it causes at least one of weight gain, an increase in the length of the small intestine, a decrease in gastrointestinal motility, and an increase in nutrient absorption.
- composition according to any one of the preceding embodiments, wherein (i) the insulin-secreting peptide is in the form of a long-acting conjugate to which a biocompatible substance capable of increasing its in vivo half-life is bound, or
- the GLP-2 is in the form of a long-acting conjugate to which a biocompatible material capable of increasing its in vivo half-life is bound, or
- Each of the insulin-secreting peptide and GLP-2 is characterized in that it is in the form of a long-acting conjugate to which a biocompatible substance capable of increasing their in vivo half-life is bound.
- X is an insulin secreting peptide or GLP-2
- L is a linker containing an ethylene glycol repeating unit
- a is 0 or a natural number, provided that when a is 2 or more, each L is independent of each other;
- F is an immunoglobulin Fc region
- the "-" is a covalent bond.
- composition according to any one of the preceding embodiments, wherein the immunoglobulin Fc region is an aglycosylated IgG4 Fc region.
- composition according to any one of the preceding embodiments, wherein L is polyethylene glycol.
- composition according to any one of the preceding embodiments, wherein the composition further comprises a pharmaceutically acceptable carrier, excipient or diluent.
- composition according to any one of the preceding embodiments, wherein the composition containing the insulin-secreting peptide is administered concurrently with the composition containing GLP-2, sequentially or in reverse order.
- Another aspect embodying the present invention is a combination comprising an insulin-secreting peptide and GLP-2.
- Another aspect embodying the present invention is a pharmaceutical composition for preventing, improving or treating short bowel syndrome, comprising the combination.
- Another aspect embodying the present invention is a pharmaceutical kit for the prevention, improvement or treatment of short bowel syndrome, comprising the combination.
- Another aspect embodying the present invention is a method for preventing, improving or treating short bowel syndrome, comprising administering and/or using the combination, pharmaceutical composition, or pharmaceutical kit to an individual in need thereof. .
- a composition containing a pharmaceutically effective amount of an insulin-secreting peptide and a composition containing a pharmaceutically effective amount of GLP-2 are administered and/or used in combination to an individual in need thereof. It is a method for preventing, improving or treating short bowel syndrome, comprising the steps.
- Another aspect embodying the present invention is for the prevention, improvement or treatment of short bowel syndrome of the combination, pharmaceutical composition, or pharmaceutical kit, and/or for the preparation of a medicament for the prevention or treatment of short bowel syndrome. is the use
- the combination administration regimen of the insulin-secreting peptide and GLP-2 according to the present invention has an improved effect compared to a single administration regimen, and thus can be usefully used for the prevention, improvement or treatment of short bowel syndrome.
- FIG. 1 is a diagram showing changes in body weight of mice according to the combined administration of an insulin-secreting peptide (GLP-1 derivative long-acting conjugate) and GLP-2 (GLP-2 derivative long-acting conjugate).
- FIG. 2 is a diagram showing changes in the length of the small intestine in mice according to the combined administration of insulin-secreting peptide (GLP-1 derivative long-acting conjugate) and GLP-2 (GLP-2 derivative long-acting conjugate).
- FIG. 3 is a diagram showing changes in gastrointestinal motility according to the combined administration of insulin-secreting peptide (GLP-1 derivative long-acting conjugate) and GLP-2 (GLP-2 derivative long-acting conjugate).
- One aspect embodying the present invention is a pharmaceutical composition for the prevention, improvement or treatment of short bowel syndrome (SBS) containing an insulin-secreting peptide, wherein the insulin-secreting peptide is a glucagon-like peptide-2 (Glucagon- like peptide-2, GLP-2) provides a pharmaceutical composition characterized in that it is administered in combination.
- SBS short bowel syndrome
- the pharmaceutical composition is a pharmaceutical composition for the prevention or treatment of short bowel syndrome containing an insulin-secreting peptide in a pharmaceutically effective amount, wherein the pharmaceutical composition is GLP-2 (eg, pharmaceutical composition). It may be characterized in that it is administered in combination with an effective amount of GLP-2), but is not limited thereto.
- GLP-2 eg, pharmaceutical composition
- Another aspect embodying the present invention is a pharmaceutical composition for the prevention, improvement or treatment of short bowel syndrome containing GLP-2, wherein the GLP-2 is administered in combination with an insulin-secreting peptide.
- the pharmaceutical composition is a pharmaceutical composition for the prevention, improvement or treatment of short bowel syndrome containing a pharmaceutically effective amount of GLP-2, wherein the pharmaceutical composition comprises an insulin-secreting peptide (eg, It may be characterized in that it is administered in combination with a pharmaceutically effective amount of an insulin-secreting peptide), but is not limited thereto.
- an insulin-secreting peptide eg, It may be characterized in that it is administered in combination with a pharmaceutically effective amount of an insulin-secreting peptide, but is not limited thereto.
- the co-administration is (i) co-administered using a pharmaceutical composition further comprising GLP-2 in the form of a mixture or separate form together with an insulin-secreting peptide, or (ii) )
- the pharmaceutical composition containing the insulin-secreting peptide may be administered in combination with a separate pharmaceutical composition containing GLP-2 simultaneously, sequentially or in reverse order, but is not limited thereto.
- Another aspect of the present invention provides a use for preventing, improving or treating short bowel syndrome using an insulin-secreting peptide and GLP-2 in combination.
- Another embodiment provides a pharmaceutical composition for preventing, improving or treating short bowel syndrome using an insulin-secreting peptide and GLP-2 in combination.
- one aspect of the present invention provides a combination, pharmaceutical composition, or pharmaceutical kit comprising an insulin-secreting peptide and GLP-2. In one embodiment, it provides a combination, pharmaceutical composition, or pharmaceutical kit for the prevention, improvement or treatment of short bowel syndrome.
- the term “combination” refers to the use of the insulin-secreting peptide and GLP-2 for combined administration, and may be understood to have the same meaning as “combined use”. This includes, but is not limited to, a pharmaceutical composition characterized in that the insulin-secreting peptide and GLP-2 are used in combination and in the form of a pharmaceutical kit.
- the insulin-secreting peptide and GLP-2 are administered as a mixture;
- the insulin-secreting peptide and GLP-2 may be administered in a separate form, but is not limited thereto.
- each of the insulin-secreting peptide and GLP-2 may be formulated as separate agents, and the separate agents may be administered simultaneously, separately, sequentially, or in reverse order.
- “combination administration”, “combination”, or “in combination” does not only mean simultaneous administration, but also the insulin-secreting peptide and GLP-2 act together on the subject so that each substance has its own function It should be understood as a dosage form capable of performing at a level equivalent to or higher than that of Accordingly, herein, when the term “combination” is used, it is to be understood that it refers to simultaneous, separate, sequential, or reverse administration, and the order is not limited. When the administration is sequential, reversed or separate, the order of administration is not particularly limited, provided that the interval between administration of the secondary component should be such that the beneficial effect of the combination is not lost.
- composition comprising a combination may be a combination itself comprising the insulin-secreting peptide and GLP-2, or it may contain the same and have therapeutic use, but is not limited thereto. .
- composition may have a use for preventing, improving or treating short bowel syndrome, but is not limited thereto.
- composition comprising a combination may be used interchangeably with “composition”.
- composition comprising the combination according to the present invention is for co-administration of the insulin-secreting peptide and GLP-2, and the insulin-secreting peptide and GLP-2 may be formulated as one formulation or separately formulated. . Specifically, the insulin-secreting peptide and GLP-2 may be administered simultaneously, separately, sequentially, or in reverse order, but is not limited thereto.
- the term "kit” may include a combination or composition according to the present invention for co-administration of the insulin-secreting peptide and GLP-2.
- the kit according to the present invention includes an insulin-secreting peptide and GLP-2 formulated as a single agent; Alternatively, it may include individual preparations of the insulin-secreting peptide and GLP-2, and may additionally include a substance necessary for co-administration of the two substances, but is not limited thereto.
- the present invention provides the combination therapy by confirming that the prevention, improvement or therapeutic effect of short bowel syndrome is dramatically increased compared to the insulin-secreting peptide alone when GLP-2 is additionally included in the insulin-secreting peptide and used in combination. became
- insulin-secreting peptide refers to a peptide having an insulin-secreting function, and can stimulate the synthesis or expression of insulin in pancreatic beta cells.
- the insulin-secreting peptide may be, for example, glucose like peptide-1 (GLP-1), exendin-3, or exendin-4, but is not limited thereto.
- GLP-1 glucose like peptide-1
- exendin-3 or exendin-4, but is not limited thereto.
- the insulin-secreting peptide includes not only the native insulin-secreting peptide, but also precursors, agonists, derivatives, fragments, and variants thereof, and their in vivo half-lives. It also includes the form of a long-acting conjugate to which a biocompatible substance that can increase
- the insulin-secreting peptide may be included in the pharmaceutical composition in a pharmaceutically effective amount.
- GLP-1 is a hormone secreted from the small intestine and generally promotes insulin biosynthesis and secretion, suppresses glucagon secretion, and promotes intracellular glucose uptake.
- the glucagon precursor is broken down into three peptides: glucagon, GLP-1, and GLP-2.
- GLP-1 refers to GLP-1(1-37), which is a form without insulin secretion function, and is processed into GLP-1(7-37) form to become active GLP-1(7-37).
- the GLP-1 (7-37) amino acid sequence is as follows.
- Exendin-3 and Exendin-4 are GLP-1 analogs or derivatives composed of 39 amino acids that show 53% amino acid sequence similarity to GLP-1, and correspond to insulin-secreting peptides.
- the amino acid sequences of exendin-3 and exendin-4 are as follows.
- HSDGT FTSDL SKQME EEAVR LFIEW LKNGG PSSGA PPPS (SEQ ID NO: 33)
- HGEGT FTSDL SKQME EEAVR LFIEW LKNGG PSSGA PPPS (SEQ ID NO: 34)
- the insulin-secreting peptide derivative has an insulin-secreting function, and has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more homology or identity with the native insulin-secreting peptide in amino acid sequence. and/or some group of amino acid residues in the insulin-secreting peptide are chemically substituted (eg, alpha-methylation, alpha-hydroxylation), removed (eg, deamination) or modified (eg, N-methylation). It may be in the form, but is not limited thereto.
- the insulin-secreting peptide derivative of the present invention is synthesized by removing the alpha amino group of the N-terminal histidine, replacing the N-terminal amino group with a hydroxyl group or a carboxyl group, N -Removing the alpha carbon of the terminal histidine and the N-terminal amino group bonded to the alpha carbon to leave only imidazo-acetyl functionalities, or modifying the N-terminal amino group with two methyl groups, etc. can be manufactured.
- the N-terminal histidine residue of the insulin-secreting peptide is imidazoacetyldeshistidine, desaminohistidine, ⁇ -hydroxyimidazopropionyldeshistidine, N-dimethylhistidine, or ⁇ - It may be an insulin-secreting peptide derivative substituted with carboxyimidazopropionyldeshistidine.
- the insulin-secreting peptide derivative may be a GLP-1 derivative
- the GLP-1 derivative includes, but is not limited to, exendin-3, exendin-4, or a derivative thereof.
- an example of the insulin-secreting peptide derivative may be a derivative in which the N-terminal amino group or amino acid residue of Exendin-4 is chemically mutated.
- imidazoacetyl deshistidyl exendin-4 imidazoacetyl-deshistidyl-exendin-4, CA-exendin-4) from which the bound N-terminal amino group has been removed, and desamino hiss from which the N-terminal amino group of exendin-4 has been removed
- Tidyl exendin-4 (desaminohistidyl exendin-4, DA-exendin-4)
- the insulin-secreting peptide fragment refers to a form in which one or more amino acids are removed and/or added to the N-terminus or C-terminus of the native insulin-secreting peptide, and the added amino acid is an amino acid that does not exist in nature (eg, D-type). amino acids) are also possible.
- the insulin-secreting peptide variant is a peptide having one or more amino acids different from the native insulin-secreting peptide, and has at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more homology or identity. It means a peptide with insulin secretion function.
- An insulin-secreting peptide agonist refers to a substance exhibiting the same biological activity as an insulin-secreting peptide by binding to an in vivo receptor of the insulin-secreting peptide regardless of the structure of the insulin-secreting peptide.
- each of the preparation methods used in the derivatives, fragments, variants and agents of the present invention may be used independently or in combination.
- insulin-secreting peptides differing in one or more amino acid sequences and deamination to the N-terminal amino acid residue are also included in the present invention.
- glucagon-like peptide-2 or “GLP-2 (Glucagon-like peptide-2) is an agonist of a glucagon-like peptide-2 receptor, which can increase the half-life of a polypeptide form or its in vivo. It may be in the form of a long-acting conjugate to which a biocompatible material is bound, but is not limited thereto.
- GLP-2 when referring to glucagon-like peptide-2 or GLP-2, not only sequences identical to native human GLP-2 but also GLP-2 derivatives are included, and biocompatible with native GLP-2 or GLP-2 derivatives. It also encompasses long-acting conjugates in which substances are bound.
- the GLP-2 may be included in a pharmaceutically effective amount in the composition or a separate composition so that it can be administered or used in combination with a pharmaceutical composition containing an insulin-secreting peptide.
- the amino acid sequence of native GLP-2 is as follows.
- HADGSFSDEMNTILDNLAARDFINWLIQTKITD (SEQ ID NO: 1)
- GLP-2 receptor agonist refers to a substance that binds to a human glucagon-like peptide-2 receptor in vivo or isolated and produces physiological activity equivalent to or similar to that of native GLP-2.
- a GLP-2 agonist may include native GLP-2 or a GLP-2 derivative.
- GLP-2 derivative refers to a peptide having at least one difference in amino acid sequence compared to native GLP-2; a peptide in which the native GLP-2 sequence is modified through modification; and/or a mimic of native GLP-2 having a preventive, therapeutic and/or ameliorating function of short bowel syndrome, such as native GLP-2.
- the GLP-2 derivative is a modification selected from the group consisting of substitution, addition, deletion, modification, and combinations thereof to at least one amino acid in the native GLP-2 sequence. may have occurred, but is not limited thereto.
- the added amino acid may be a non-natural amino acid (eg, D-type amino acid), and it is also possible to substitute a non-natural amino acid in addition to the natural amino acid.
- the added amino acid sequence may be derived from native GLP-2, but is not limited thereto.
- the modification of an amino acid is combined with substitution, addition, deletion, or a combination of at least one amino acid; Or independently, it means that some groups of amino acid residues are chemically substituted (eg, alpha-methylation, alpha-hydroxylation, or azido group), removed (eg, deamination) and/or modified (eg, N-methylation) can, but is not limited thereto.
- the derivative of GLP-2 of the present invention contains at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or more of native GLP-2 and amino acid sequence.
- an N-terminal amino group may be substituted, removed, or modified, but is not limited thereto.
- GLP-2 of the present invention is a method of removing the alpha amino group of histidine at the N-terminus to prevent binding to the N-terminus, which is an important site for the in vivo activity of GLP-2, when preparing a long-acting conjugate; Synthesis method by substituting an amino group with a hydroxyl group or a carboxyl group, imidazo-acetyl action by removing the alpha carbon of the N-terminal histidine and the N-terminal amino group bonded to the alpha carbon It can be prepared through a method of leaving only a group, a method of modifying an N-terminal amino group with two methyl groups, and the like.
- the GLP-2 derivative is imidazoacetyl-deshistidyl GLP-2 (imidazoacetyl-deshistidyl- GLP-2, CA-GLP-2), desaminohistidyl GLP-2 from which the N-terminal amino group of GLP-2 has been removed (desaminohistidyl GLP-2, DA-GLP-2), the N-terminal amino group of GLP-2 Beta-hydroxyimidazopropionyldeshistidyl GLP-2 ( ⁇ -hydroxyimidazopropionyldeshistidyl GLP-2, HY-GLP-2) substituted with a hydroxyl group, the N-terminal amino group of GLP-2 is modified with two methyl groups N-dimethylhistidyl GLP-2 (N-dimethylhistidyl GLP-2, DM-GLP-2), or beta-carboxyimidazopropionyldeshistidyl-GLP in which the N-terminal
- imidazoacetyldeshistidyl (din), desaminohistidyl (din), beta-hydroxyimidazopropionyldeshistidyl (din), N-dimethylhistidyl (din), and beta-carboxyimidazo Propionyldeshistidyl (din) may be used in the same meaning as imidazoacetyl, des-amino-histidyl, beta-hydroxy-imidazopropionyl, dimethyl-histidyl, beta-carboxyl-imidazopropionyl, respectively. .
- the GLP-2 derivative may be one in which at least one amino acid of amino acids 1, 2, 30 and 33 in SEQ ID NO: 1 is modified, but is not limited thereto.
- the modification may be a modification selected from the group consisting of substitution, addition, deletion, modification, and combinations thereof of at least one amino acid, wherein the added amino acid is a non-natural amino acid (eg, a D-type amino acid) Also, it is possible to substitute non-natural amino acids in addition to natural amino acids.
- the added amino acid sequence may be derived from native GLP-2, but is not limited thereto.
- the modification of an amino acid is combined with substitution, addition, deletion, or a combination of at least one amino acid; Or independently, it means that some groups of amino acid residues are chemically substituted (eg, alpha-methylation, alpha-hydroxylation, or azido group), removed (eg, deamination) and/or modified (eg, N-methylation) can, but is not limited thereto.
- the GLP-2 derivative may comprise, but is not limited to, the amino acid sequence of the following general formula 1:
- X 1 is histidine, imidazoacetyldeshistidine, desaminohistidine, ⁇ -hydroxyimidazopropionyldeshistidine, N-dimethylhistidine, or ⁇ -carboxyimidazopropionyldeshistidine;
- X 2 is alanine, glycine, or Aib (2-aminoisobutyric acid);
- X 30 is lysine or arginine
- X 34 is absent or is lysine, arginine, glutamine, histidine, 6-azidolysine, or cysteine.
- the GLP-2 derivative may include, but is not limited to, an amino acid sequence of the following general formula 2:
- X 1 is histidine, imidazoacetyldeshistidine, desaminohistidine, ⁇ -hydroxyimidazopropionyldeshistidine, N -dimethylhistidine, or ⁇ -carboxyimidazopropionyldeshistidine;
- X 2 is alanine, glycine, or Aib (2-aminoisobutyric acid);
- X 30 is lysine or arginine
- X 34 is one or more optional amino acids or one or more optional amino acids to which a modification has occurred.
- the amino acid may be a natural amino acid or a non-natural amino acid, and the modification of the amino acid is as described above.
- sequence identical to SEQ ID NO: 1 among the amino acid sequences of Formula 1 or 2 may be excluded from the GLP-2 derivative, but is not limited thereto.
- the GLP-2 derivative of the present invention is a substitution of glycine or Aib (2-aminoisobutyric acid) for alanine, which is the second amino acid of native GLP-2, substitution of lysine, which is the 30th amino acid, with arginine, or these It may have a combination of, but is not limited thereto.
- the GLP-2 derivative is a thiol group (eg, cysteine), an amino group (eg, lysine, arginine, glutamine or histidine) at the C-terminus (eg, the 33rd amino acid), or an azide group ( For example, 6-azidolysine) may be introduced, but is not limited thereto.
- a GLP-2 conjugate with a selectively controlled binding site can be prepared using this.
- one end of the linker is bound to a hydroxyl group, a thiol group, an amino group, or an azide group of the GLP-2 derivative, and a substance capable of increasing the half-life in vivo to the other end of the linker (e.g., immunoglobulin) Fc region) may be bound.
- the thiol group, amino group, or azide group may be introduced by adding an amino acid to GLP-2, but is not limited thereto.
- the thiol group is introduced by adding cysteine (C) to GLP-2; Amino groups are introduced by addition of lysine (K), arginine (R), glutamine (Q) or histidine (H); The azide group may be introduced by adding 6-azidolysine ( AZ K), but is not limited thereto.
- At least one residue may be cysteine, lysine, arginine, glutamine, histidine or 6-azidolysine, but is not limited thereto.
- the GLP-2 derivative of the present invention includes substitution of alanine, the second amino acid of native GLP-2, with glycine, and introduction of a thiol group (eg, cysteine) at the C-terminus, more specifically N - May include imidazoacetyl deshistidine in which the alpha carbon of the histidine residue, which is the first amino acid at the terminal, and the N-terminal amino group bonded to the alpha carbon are removed, for example, it may have the amino acid sequence of SEQ ID NO: 2, but is not limited thereto does not
- the GLP-2 derivative of the present invention includes substitution of alanine, which is the second amino acid of native GLP-2, with glycine and introduction of an amino group (eg, lysine) at the C-terminus, more specifically N - May include imidazoacetyldeshistidine in which the alpha carbon of the histidine residue, which is the first amino acid at the terminal, and the N-terminal amino group bonded to the alpha carbon have been removed, for example, it may have the amino acid sequence of SEQ ID NO: 3, but is not limited thereto does not
- the GLP-2 derivative of the present invention contains alanine as the second amino acid of native GLP-2 and glycine, lysine at the 30th amino acid of native GLP-2 with arginine, and the C-terminal It includes the introduction of an amino group (eg, lysine), and more specifically, may include imidazoacetyldeshistidine in which the N-terminal amino group bonded to the alpha carbon and the alpha carbon of the histidine residue, which is the first N-terminal amino acid, has been removed. and, for example, may have the amino acid sequence of SEQ ID NO: 4, but is not limited thereto.
- the GLP-2 derivative of the present invention includes substitution of alanine, the second amino acid of native GLP-2, with glycine, and introduction of an azide group (eg, 6-azidolysine) at the C-terminus, , more specifically, may include imidazoacetyl deshistidine in which the N-terminal amino group bonded to the alpha carbon and the alpha carbon of the histidine residue, which is the first N-terminal amino acid, has been removed, for example, it may have the amino acid sequence of SEQ ID NO: 5
- the present invention is not limited thereto.
- the GLP-2 derivative of the present invention contains alanine as the second amino acid of native GLP-2 and glycine, lysine at the 30th amino acid of native GLP-2 with arginine, and the C-terminal It may include introduction of a thiol group (eg, cysteine), more specifically imidazoacetyldeshistidine in which the N-terminal amino group bonded to the alpha carbon and the alpha carbon of the histidine residue, which is the first N-terminal amino acid, has been removed. and, for example, may have the amino acid sequence of SEQ ID NO: 6, but is not limited thereto.
- a thiol group eg, cysteine
- imidazoacetyldeshistidine more specifically imidazoacetyldeshistidine in which the N-terminal amino group bonded to the alpha carbon and the alpha carbon of the histidine residue, which is the first N-terminal amino acid, has been removed.
- SEQ ID NO: 6 but is not
- the GLP-2 derivative of the present invention comprises substitution of alanine, the second amino acid of native GLP-2, with 2-aminoisobutyric acid, and introduction of a thiol group (eg, cysteine) at the C-terminus,
- a thiol group eg, cysteine
- it may have the amino acid sequence of SEQ ID NO: 8, and more specifically, may include imidazoacetyldeshistidine in which the N-terminal amino group bonded to the alpha carbon and the alpha carbon of the histidine residue, which is the first N-terminal amino acid, has been removed.
- the GLP-2 derivatives of SEQ ID Nos: 2 to 8 are shown in Table 1 below.
- ca H is substituted with imidazoacetyl deshistidine instead of histidine
- Aib is 2-aminoisobutyric acid
- AZ K is 6-azido-L-lysine (6-azido- L-lysyine).
- GLP-2 may be a peptide comprising the specific sequence described above, or a peptide comprising (or essentially consisting of) the specific sequence described above, but is not limited thereto.
- X 2 is glycine or Aib
- X 30 is lysine or arginine
- X 2 is glycine or Aib
- X 30 may be lysine or arginine, but is not limited thereto.
- the GLP-2 derivative is represented by Formula 1 or 2
- X 1 is imidazoacetyldeshistidine
- X 2 is glycine
- X 30 is lysine
- X 34 is cysteine
- X 1 is imidazoacetyldeshistidine
- X 2 is glycine
- X 30 is lysine
- X 34 is lysine
- X 1 is imidazoacetyldeshistidine
- X 2 is glycine
- X 30 is arginine
- X 34 is lysine
- X 1 is imidazoacetyldeshistidine
- X 2 is glycine
- X 30 is lysine
- X 34 is 6-azidolysine
- X 1 is imidazoacetyldeshistidine
- X 2 is glycine
- X 30 is arginine
- X 34 is cysteine
- X 1 is imidazoacetyldeshistidine
- X 2 is Aib
- X 30 is lysine
- X 34 is cysteine
- X 1 may be histidine
- X 2 may be Aib
- X 30 may be lysine
- X 34 may be cysteine, but is not limited thereto.
- modifications for the preparation of agonists, fragments, variants and derivatives of native GLP-2 include modifications using L-form or D-form amino acids, and/or non-natural amino acids; and/or modifying the native sequence by modification or post-translational modification (eg, methylation, acylation, ubiquitination, intramolecular covalent bonding, etc.).
- the GLP-2 or GLP-2 derivative is protected from proteolytic enzymes in vivo and its N-terminus and/or C-terminus is chemically modified or protected with an organic group to increase stability,
- the GLP-2 or GLP-2 derivative may be in a modified form by adding amino acids to the terminal and the like.
- the N-terminus is acetylated and/or the C-terminal amidation is performed to remove these charges.
- it is not particularly limited thereto.
- GLP-2 or a GLP-2 derivative may have its C-terminus unmodified or amidated, but is not limited thereto.
- the insulin-secreting peptide and/or GLP-2 may be in the form of a long-acting conjugate to which a biocompatible substance capable of increasing each in vivo half-life is bound, but is not limited thereto.
- the long-acting conjugate may exhibit increased potency persistence compared to an insulin-secreting peptide or a derivative of GLP-2 to which a biocompatible material (eg, an immunoglobulin Fc region) is not bound, and in the present invention, an insulin-secreting peptide or GLP A conjugate containing an insulin-secreting peptide or GLP-2, which has an increased half-life by binding of a biocompatible substance to -2, is respectively referred to as “insulin-secreting peptide long-acting conjugate or insulin-secreting peptide long-acting conjugate” or “GLP-2 long-acting conjugate”, respectively. conjugate or a long-acting conjugate of GLP-2.
- the long-acting binder is used interchangeably with the
- the insulin-secreting peptide is in the form of a long-acting conjugate to which a biocompatible substance capable of increasing its in vivo half-life is bound, or
- the GLP-2 is in the form of a long-acting conjugate to which a biocompatible material capable of increasing its in vivo half-life is bound, or
- Each of the insulin-secreting peptide and GLP-2 may be in the form of a long-acting conjugate to which a biocompatible substance capable of increasing their in vivo half-life is bound.
- the combination may be non-naturally occurring.
- connection between the insulin-secreting peptide or GLP-2 and the biocompatible material may be a physical or chemical bond, a non-covalent bond or a covalent bond, and specifically a covalent bond.
- the present invention is not limited thereto.
- the method for linking the insulin-secreting peptide or GLP-2 and the biocompatible material (eg, immunoglobulin Fc region) in the long-acting conjugate is not particularly limited, but the insulin-secreting peptide or GLP-2 and the biocompatible material (eg, through a linker)
- the insulin-secreting peptide or GLP-2 and the biocompatible material eg, through a linker
- immunoglobulin Fc regions may be linked to each other.
- Korean Patent Application Laid-Open No. 10-2019-0037181 relating to a long-acting conjugate of GLP-2 is incorporated herein by reference.
- the long-acting conjugate of the insulin-secreting peptide or GLP-2 of the present invention may have the structure of Formula 1 below, but is not limited thereto.
- X is an insulin secreting peptide or GLP-2
- L is a linker (eg, a linker containing ethylene glycol repeat units
- a is 0 or a natural number, provided that when a is 2 or more, each L is independent of each other;
- F is a biocompatible substance capable of increasing the in vivo half-life of X (eg, an immunoglobulin Fc region);
- the “-” is a chemical bond (eg, a covalent bond).
- X and L, and L and F may be connected to each other by a covalent bond, and in this case, the conjugate may be a conjugate in which X, L, and F are each connected through a covalent bond in the order of Formula 1 .
- F may be directly connected to X (ie, a is 0 in Formula 1) or connected through a linker (L).
- F is X, that is, a substance capable of increasing the half-life of the insulin-secreting peptide or GLP-2 according to the present invention, and corresponds to one component of a moiety constituting the conjugate of the present invention.
- the F may be bonded to each other by a covalent chemical bond or a non-covalent chemical bond with X, and F and X may be bonded to each other through L through a covalent chemical bond, a non-covalent chemical bond, or a combination thereof.
- the F is a material capable of increasing the in vivo half-life of X is a biocompatible material, for example, a high molecular polymer, fatty acid, cholesterol, albumin and fragments thereof, an albumin binding material, a polymer of a repeating unit of a specific amino acid sequence, an antibody , antibody fragments, FcRn binding materials, in vivo connective tissue, nucleotides, fibronectin, transferrin, saccharides, heparin, and elastin may be selected from the group consisting of, but is not particularly limited thereto.
- a biocompatible material for example, a high molecular polymer, fatty acid, cholesterol, albumin and fragments thereof, an albumin binding material, a polymer of a repeating unit of a specific amino acid sequence, an antibody , antibody fragments, FcRn binding materials, in vivo connective tissue, nucleotides, fibronectin, transferrin, saccharides, heparin, and elastin
- the elastin may be human tropoelastin, a water-soluble precursor, and may be a polymer of some sequences or some repeating units of these, for example, all cases of an elastin-like polypeptide, but is not particularly limited thereto. .
- polymer polymer examples include polyethylene glycol (PEG), polypropylene glycol, ethylene glycol-propylene glycol copolymer, polyoxyethylated polyol, polyvinyl alcohol, polysaccharide, polyvinyl ethyl ether, biodegradable polymer, lipid polymer, chitin, and a high molecular polymer selected from the group consisting of hyaluronic acid, oligonucleotides, and combinations thereof, and the polysaccharide may include dextran, but is not particularly limited thereto.
- PEG polyethylene glycol
- polypropylene glycol ethylene glycol-propylene glycol copolymer
- polyoxyethylated polyol polyvinyl alcohol
- polysaccharide polyvinyl ethyl ether
- biodegradable polymer lipid polymer
- chitin examples of the polysaccharide may include dextran, but is not particularly limited thereto.
- polyethylene glycol is a term encompassing all forms of ethylene glycol homopolymer, PEG copolymer, or monomethyl-substituted PEG polymer (mPEG), but is not particularly limited thereto.
- biocompatible material includes, but is not limited to, poly-amino acids such as poly-lysine, poly-aspartic acid and poly-glutamic acid.
- the fatty acid may have a binding force with albumin in vivo, but is not particularly limited thereto.
- the F may be an FcRn-binding substance, and specifically, the FcRn-binding substance may be an immunoglobulin Fc region, more specifically an IgG Fc region, more specifically an aglycosylated IgG4 Fc area, but is not particularly limited thereto.
- the F eg, immunoglobulin Fc region
- the F is a dimer consisting of two polypeptide chains, and one end of L is linked to only one of the two polypeptide chains.
- the long-acting conjugate of the present invention may be one in which an insulin-secreting peptide or GLP-2 and an immunoglobulin Fc region are linked, but is not limited thereto.
- immunoglobulin Fc region refers to a heavy chain constant region excluding the heavy chain and light chain variable regions of an immunoglobulin.
- the immunoglobulin Fc region may include a heavy chain constant region 2 (CH2) and/or heavy chain constant region 3 (CH3) portion, and more specifically, a hinge region (means all or part of the hinge region). .) may be further included.
- the immunoglobulin Fc region may be one component constituting a moiety of the conjugate of the present invention. Specifically, it corresponds to F in Formula 1 above.
- the Fc region not only the native sequence obtained from papain digestion of immunoglobulin, but also derivatives and substitutions thereof, for example, one or more amino acid residues in the native sequence are transformed by deletion, insertion, non-conservative or conservative substitution, or a combination thereof. It includes even modified variants such as sequences that are different from the natural form due to the The above derivatives, substituents and variants are premised on retaining the ability to bind FcRn.
- the F (eg, immunoglobulin Fc region) has a structure in which two polypeptide chains are linked by a disulfide bond, and may be a structure in which only one of the two chains is linked through a nitrogen atom, but is limited thereto doesn't happen
- the linkage through the nitrogen atom may be connected through reductive amination to the epsilon amino atom or the N-terminal amino group of lysine.
- Reductive amination reaction means a reaction in which an amine group or an amino group of a reactant reacts with an aldehyde (i.e., a functional group capable of reductive amination) of another reactant to form an amine, and then forms an amine bond by a reduction reaction, It is an organic synthesis reaction well known in the art.
- aldehyde i.e., a functional group capable of reductive amination
- the immunoglobulin Fc region may be linked through its N-terminal nitrogen atom.
- the immunoglobulin Fc region may include a hinge region in the heavy chain constant region, but is not limited thereto.
- the immunoglobulin Fc region may include a specific hinge sequence at the N-terminus.
- flankinge sequence refers to a region that is located on a heavy chain and forms a dimer of an immunoglobulin Fc region through an inter disulfide bond.
- the hinge sequence may be mutated to have only one cysteine residue by deleting a portion of the hinge sequence having the following amino acid sequence, but is not limited thereto:
- the hinge sequence may include only one cysteine residue by deleting the 8th or 11th cysteine residue in the hinge sequence of SEQ ID NO: 11.
- the hinge sequence of the present invention may be composed of 3 to 12 amino acids, including only one cysteine residue, but is not limited thereto.
- the hinge sequence of the present invention may have the following sequence: Glu-Ser-Lys-Tyr-Gly-Pro-Pro-Pro-Ser-Cys-Pro (SEQ ID NO: 12), Glu-Ser- Lys-Tyr-Gly-Pro-Pro-Cys-Pro-Ser-Pro (SEQ ID NO: 13), Glu-Ser-Lys-Tyr-Gly-Pro-Pro-Cys-Pro-Ser (SEQ ID NO: 14), Glu- Ser-Lys-Tyr-Gly-Pro-Pro-Cys-Pro-Pro (SEQ ID NO: 15), Lys-Tyr-Gly-Pro-Pro-Cys-Pro-Ser (SEQ ID NO: 16), Glu-Ser-Lys- Tyr-Gly-Pro-Pro-Cys (SEQ ID NO: 17), Glu-Lys-Tyr-Gly-Pro-Pro-Cys (SEQ ID NO: 18),
- the hinge sequence may include the amino acid sequence of SEQ ID NO: 21 (Pro-Ser-Cys-Pro) or SEQ ID NO: 30 (Ser-Cys-Pro), but is not limited thereto.
- the N-terminal of the immunoglobulin Fc region in the conjugate is proline, and in this conjugate, the Fc region is linked to a linker through the nitrogen atom of the proline.
- the immunoglobulin Fc region may be in the form of a dimer in which two chains of the immunoglobulin Fc region form a homodimer or a heterodimer due to the presence of a hinge sequence.
- the conjugate of Formula 1 of the present invention may be in a form in which one end of the linker is linked to one chain of the immunoglobulin Fc region of the dimer, but is not limited thereto.
- N-terminus refers to the amino terminus of a protein or polypeptide, and 1, 2, 3, 4, 5, 6, It may include up to 7, 8, 9, or 10 or more amino acids.
- the immunoglobulin Fc region of the present invention may include a hinge sequence at the N-terminus, but is not limited thereto.
- part or all of the heavy chain constant region 1 (CH1) and/or the light chain constant region except for only the heavy and light chain variable regions of immunoglobulin 1 (CL1) may be an extended Fc region. Also, it may be a region in which some fairly long amino acid sequences corresponding to CH2 and/or CH3 have been removed.
- the immunoglobulin Fc region of the present invention comprises 1) a CH1 domain, a CH2 domain, a CH3 domain and a CH4 domain, 2) a CH1 domain and a CH2 domain, 3) a CH1 domain and a CH3 domain, 4) a CH2 domain and a CH3 domain, 5) a combination of one or two or more of the CH1 domain, the CH2 domain, the CH3 domain and the CH4 domain with an immunoglobulin hinge region (or a part of the hinge region), or 6) a dimer of each domain of the heavy chain constant region and the light chain constant region
- the present invention is not limited thereto.
- the immunoglobulin Fc region may be in a dimeric form, and one molecule of X may be covalently linked to one Fc region in the dimeric form. , wherein the immunoglobulin Fc and X may be linked to each other by one and the same linker.
- the immunoglobulin Fc and X may be connected to each other by a linker.
- the immunoglobulin Fc region of the present invention includes a native amino acid sequence as well as a sequence derivative thereof.
- An amino acid sequence derivative means that one or more amino acid residues in a natural amino acid sequence have a different sequence by deletion, insertion, non-conservative or conservative substitution, or a combination thereof.
- amino acid residues 214 to 238, 297 to 299, 318 to 322, or 327 to 331 known to be important for binding may be used as suitable sites for modification.
- various types of derivatives are possible, such as a site capable of forming a disulfide bond is removed, some amino acids at the N-terminus of native Fc are removed, or a methionine residue may be added to the N-terminus of native Fc do.
- the complement binding site eg, the C1q binding site
- the ADCC antibody dependent cell mediated cytotoxicity
- the above-described Fc derivative may exhibit biological activity equivalent to that of the Fc region of the present invention, and may have increased structural stability to heat, pH, etc. of the Fc region.
- the Fc region may be obtained from a native type isolated in vivo from animals such as humans, cows, goats, pigs, mice, rabbits, hamsters, rats or guinea pigs, or obtained from transformed animal cells or microorganisms. It may be recombinant or a derivative thereof.
- the method of obtaining from the native type may be a method of obtaining whole immunoglobulin by isolating it from a living body of a human or animal and then treating it with a proteolytic enzyme. When treated with papain, it is cleaved into Fab and Fc, and when treated with pepsin, it is cleaved into pF'c and F(ab)2.
- Fc or pF'c may be separated using size-exclusion chromatography or the like.
- it is a recombinant immunoglobulin Fc region obtained from a human-derived Fc region from a microorganism.
- the immunoglobulin Fc region may have a native sugar chain, an increased sugar chain compared to the native type, a decreased sugar chain compared to the native type, or a form in which the sugar chain is removed.
- Conventional methods such as chemical methods, enzymatic methods, and genetic engineering methods using microorganisms may be used for the increase or decrease or removal of such immunoglobulin Fc sugar chains.
- the immunoglobulin Fc region from which the sugar chains are removed from the Fc has significantly reduced binding to complement (c1q) and reduced or eliminated antibody-dependent cytotoxicity or complement-dependent cytotoxicity, so that unnecessary immune responses in vivo are not induced. does not In this respect, a form more suitable for the original purpose as a drug carrier will be an immunoglobulin Fc region in which sugar chains are removed or non-glycosylated.
- deglycosylation refers to an Fc region from which sugars have been removed with an enzyme
- aglycosylation refers to an Fc region that is not glycosylated by production in prokaryotes, in a more specific embodiment, in E. coli. .
- the immunoglobulin Fc region may be of human or animal origin, such as cattle, goats, pigs, mice, rabbits, hamsters, rats, guinea pigs, and in a more specific embodiment, human origin.
- the immunoglobulin Fc region may be an Fc region derived from IgG, IgA, IgD, IgE, or IgM, or a combination or hybrid thereof. In a more specific embodiment, it is derived from IgG or IgM, which is most abundant in human blood, and in a more specific embodiment it is derived from IgG, which is known to enhance the half-life of ligand binding proteins. In an even more specific embodiment, the immunoglobulin Fc region is an IgG4 Fc region, and in the most specific embodiment, the immunoglobulin Fc region is a non-glycosylated Fc region derived from human IgG4, but is not limited thereto.
- the immunoglobulin Fc region is a fragment of human IgG4 Fc, and is a homodimer in which two monomers are linked through a disulfide bond (inter-chain form) between cysteine, the 3rd amino acid of each monomer.
- the homodimer may have/have a disulfide bond between cysteines at positions 35 and 95 and between cysteines at positions 141 and 199 in each monomer, i.e., two disulfide bonds (intra-chain form).
- the number of amino acids of each monomer may consist of 221 amino acids, and the amino acids forming a homodimer may consist of a total of 442 amino acids, but is not limited thereto.
- the immunoglobulin Fc region is a homodimer comprising the amino acid sequence of SEQ ID NO: 35 (consisting of 442 amino acids) (wherein, two monomers having the amino acid sequence of SEQ ID NO: 31 (consisting of 221 amino acids) are 3 of each monomer A homodimer is formed through a disulfide bond between cysteines, which are amino acids, and the monomers of the homodimer each independently form an internal disulfide bond between cysteines at positions 35 and 95 and an internal disulfide bond between cysteines at positions 141 and 199. ), but is not limited thereto.
- the term "combination" with respect to an immunoglobulin Fc region means that when a dimer or multimer is formed, a polypeptide encoding a single-chain immunoglobulin Fc region of the same origin forms a bond with a single-chain polypeptide of a different origin. means to do That is, it is possible to prepare a dimer or multimer from two or more Fc regions selected from the group consisting of IgG Fc, IgA Fc, IgM Fc, IgD Fc and IgE Fc region.
- hybrid is a term meaning that sequences corresponding to immunoglobulin Fc regions of two or more different origins exist in a single-chain immunoglobulin constant region.
- various types of hybrids are possible. That is, a hybrid of domains consisting of 1 to 4 domains from the group consisting of CH1, CH2, CH3 and CH4 of IgG Fc, IgM Fc, IgA Fc, IgE Fc and IgD Fc is possible, and may include a hinge.
- IgG can also be divided into subclasses of IgG1, IgG2, IgG3 and IgG4, and in the present invention, a combination thereof or hybridization thereof is also possible. Specifically, the subclasses of IgG2 and IgG4, and most specifically, the Fc region of IgG4 having little effector function such as complement dependent cytotoxicity (CDC).
- CDC complement dependent cytotoxicity
- the above-described conjugate may have an increased duration of effect compared to the native insulin-secreting peptide or native GLP-2, or compared to X in which F is not modified. It includes, but is not limited to, the form encapsulated in nanoparticles.
- the linker L may be a peptidic linker or a non-peptidyl linker (eg, a linker containing an ethylene glycol repeating unit).
- L is a peptidic linker
- it may include one or more amino acids, for example, 1 to 1000 amino acids, but is not particularly limited thereto.
- various known peptide linkers may be used in the present invention to link F and X, and examples thereof include a [GS]x linker, [GGGS]x linker, and [GGGGS]x linker, where x is It may be 1 or more natural numbers. However, it is not limited to the above example.
- non-peptidyl linker includes a biocompatible polymer in which two or more repeating units are bonded. The repeating units are linked to each other through any covalent bond other than a peptide bond.
- the non-peptidyl linker may be one component constituting a moiety of the conjugate of the present invention, and corresponds to L in Formula 1 above.
- the non-peptidyl linker that can be used in the present invention may be used without limitation as long as it is a polymer resistant to proteolytic enzymes in vivo.
- the non-peptidyl linker may be used in combination with a non-peptidyl polymer.
- non-peptidyl linker may include polyethylene glycol, polypropylene glycol, copolymers of ethylene glycol and propylene glycol, polyoxyethylated polyols, polyvinyl alcohol, polysaccharides (eg, dextran, etc.), poly It may be selected from the group consisting of vinyl ethyl ether, biodegradable polymers such as polylactic acid (PLA) and polylactic-glycolic acid (PLGA), lipid polymers, chitin, hyaluronic acid, oligonucleotides, and combinations thereof.
- PLA polylactic acid
- PLGA polylactic-glycolic acid
- lipid polymers chitin, hyaluronic acid, oligonucleotides, and combinations thereof.
- the non-peptidyl linker that can be used in the present invention can be used without limitation as long as it is a polymer resistant to protease in vivo.
- the molecular weight of the non-peptidyl polymer is in the range of more than 0 to about 100 kDa, from about 1 to about 100 in the range of kDa, specifically in the range of about 1 to 50 kDa, in the range of about 1 to about 20 kDa, in the range of about 1 to about 10 kDa, or in the range of about 3.4 kDa to 10 kDa.
- non-peptidyl linker may be a linker containing an ethylene glycol repeating unit, for example, polyethylene glycol, and also derivatives thereof known in the art and easily at the level of skill in the art. Derivatives that can be prepared are also included in the scope of the present invention.
- the repeating unit of the non-peptidyl linker may be an ethylene glycol repeating unit, and specifically, the non-peptidyl linker may include an ethylene glycol repeating unit and a functional group used in the preparation of the conjugate at the terminal thereof.
- the long-acting conjugate according to the present invention may be in a form in which X and F are linked through the functional group, but is not limited thereto.
- the non-peptidyl linker may include two, or three or more functional groups, and each functional group may be the same or different from each other, but is not limited thereto.
- the linker may be polyethylene glycol (PEG) represented by the following formula (4), but is not limited thereto:
- the PEG moiety in the long-acting conjugate may include not only the -(CH 2 CH 2 O) n -structure, but also an oxygen atom intervening between the linking element and the -(CH 2 CH 2 O) n -, but this It is not limited.
- the conjugate may have a structure in which the insulin-secreting peptide or GLP-2 and the immunoglobulin Fc region (F) are covalently linked through a linker containing an ethylene glycol repeating unit, but is limited thereto not.
- the polyethylene glycol is a term encompassing all forms of ethylene glycol homopolymer, PEG copolymer, or monomethyl-substituted PEG polymer (mPEG), but is not particularly limited thereto.
- the ethylene glycol repeating unit may be represented by, for example, [OCH2CH2]n, and the value of n is a natural number, and the average molecular weight of the [OCH2CH2]n site in the peptide conjugate, for example, the number average molecular weight is greater than 0. It may be set to be about 100 kDa, but is not limited thereto.
- the n value is a natural number
- the average molecular weight of the [OCH2CH2]n site in the peptide conjugate is about 1 to about 100 kDa, about 1 to about 80 kDa, about 1 to about 50 kDa, about 1 to about 30 kDa, about 1 to about 25 kDa, about 1 to about 20 kDa, about 1 to about 15 kDa, about 1 to about 13 kDa, about 1 to about 11 kDa, about 1 to about 10 kDa, about 1 to about 8 kDa, about 1 to about 5 kDa, about 1 to about 3.4 kDa, about 3 to about 30 kDa, about 3 to about 27 kDa, about 3 to about 25 kDa, about 3 to about 22 kDa, about 3 to about 20 kDa, about 3 to about 18 kDa, about 3 to about 16 kDa, about 3 to about 100 kDa, about 1 to about 80 k
- the term “about” includes all values within a range including ⁇ 0.5, ⁇ 0.4, ⁇ 0.3, ⁇ 0.2, ⁇ 0.1, etc., and includes all values in a range equal to or similar to the value following the term about, but not limited
- non-peptidyl linker of the present invention to be coupled to the immunoglobulin Fc region, not only one type of polymer but also a combination of different types of polymers may be used.
- both ends of the non-peptidyl linker may bind to a thiol group, an amino group, a hydroxyl group of the immunoglobulin Fc region, and a thiol group, an amino group, an azide group, or a hydroxyl group of GLP-2. , but not limited thereto.
- the non-peptidyl linker includes a reactive group capable of binding to immunoglobulin Fc and insulin-secreting peptide or GLP-2 at both ends, specifically, a thiol group of a cysteine in the immunoglobulin Fc region; an amino group located at the N-terminus, lysine, arginine, glutamine and/or histidine; and/or a thiol group of a cysteine of GLP-2 combined with a hydroxyl group located at the C-terminus; amino groups of lysine, arginine, glutamine and/or histidine; azide group of azidolysine; and/or a reactive group capable of bonding to a hydroxyl group, but is not limited thereto.
- the reactive group of the non-peptidyl polymer may be at least one selected from the group consisting of an aldehyde group, a maleimide group, and a succinimide derivative, but is not limited thereto.
- a propion aldehyde group or a butyl aldehyde group may be exemplified as the aldehyde group, but the present invention is not limited thereto.
- succinimidyl carboxymethyl, succinimidyl valerate, succinimidyl methylbutanoate, succinimidyl methylpropionate, succinimidyl butanoate, succinimidyl propionate, N -Hydroxysuccinimide, hydroxy succinimidyl or succinimidyl carbonate may be used, but not limited thereto.
- the non-peptidyl linker may be connected to a biocompatible material (eg, immunoglobulin Fc) and an insulin-secreting peptide or GLP-2 through the above-described reactive group to be converted into a non-peptidyl polymer linkage.
- a biocompatible material eg, immunoglobulin Fc
- an insulin-secreting peptide or GLP-2 through the above-described reactive group to be converted into a non-peptidyl polymer linkage.
- the final product resulting from reductive alkylation with aldehyde bonds is much more stable than those linked with amide bonds.
- the aldehyde reactive group selectively reacts with the N-terminus at a low pH, and can form a covalent bond with a lysine residue at a high pH, for example, pH 9.0.
- the terminal reactive groups of the non-peptidyl linker of the present invention may be the same as or different from each other.
- the non-peptidyl linker may have an aldehyde group reactive group at the terminal, and the non-peptidyl linker may have an aldehyde group and a maleimide reactive group at the terminal, respectively, or have an aldehyde group and a succinimide reactive group at the terminal, respectively can, but is not limited thereto.
- it may have a maleimide group at one end and an aldehyde group, propionaldehyde group or butyl aldehyde group at the other end.
- it may have a succinimidyl group at one end and a propionaldehyde group or a butyl aldehyde group at the other end.
- the hydroxyl group can be activated into the various reactive groups by a known chemical reaction, or a commercially available polyethylene glycol having a modified reactive group is used. It can be used to prepare the conjugate of the present invention.
- the reactive group of the non-peptidyl linker may be linked to a cysteine residue of an insulin-secreting peptide or GLP-2, more specifically, a -SH group of cysteine, but is not limited thereto.
- maleimide-PEG-aldehyde is used, the maleimide group is linked to the -SH group of the insulin-secreting peptide or GLP-2 by a thioether bond, and the aldehyde group is reductively alkylated with the -NH 2 group of immunoglobulin Fc. It may be connected through a reaction, but is not limited thereto, and this corresponds to one example.
- the N-terminal amino group of the immunoglobulin Fc region is linked to an oxygen atom located at one end of PEG through a linker functional group having a structure of -CH 2 CH 2 CH 2 -, -PEG-O -CH 2 CH 2 CH 2 NH-Can form the same structure as immunoglobulin Fc, and form a structure in which one end of PEG is linked to a sulfur atom located at GLP-2 or cysteine of GLP-2 through a thioether bond.
- the above-mentioned thioether bond is may contain the structure of
- the reactive group of the non-peptidyl linker may be linked to -NH 2 located at the N-terminus of the immunoglobulin Fc region, but this corresponds to one example.
- the insulin-secreting peptide or GLP-2 may be linked to a non-peptidyl linker having a reactive group through the C-terminus, but this corresponds to one example.
- C-terminal refers to the carboxy terminus of a peptide, and refers to a position capable of binding to a non-peptide polymer for the purpose of the present invention.
- it may include all amino acid residues around the C-terminus as well as the most terminal amino acid residue at the C-terminus, and specifically include the first to 20th amino acid residues from the most terminal.
- the conjugate of Formula 1 may have a structure of Formula 2 or 3 below.
- X is the peptide of Formula 1 described above;
- F is an immunoglobulin Fc fragment
- n may be a natural number. In this case, the description of n is the same as described above.
- the long-acting conjugate of Formula 2 has a structure in which X of the insulin-secreting peptide or GLP-2 and F of the immunoglobulin Fc region are covalently linked through an ethylene glycol repeat, and each X is represented by Formula 2 In the succinimide ring of , F may be linked to an oxypropylene group of Formula 2.
- the long-acting conjugate of Formula 3 is a structure in which X of the insulin-secreting peptide or GLP-2 and F of the immunoglobulin Fc region are covalently linked through an ethylene glycol repeat, wherein each X is an oxypropylene group of Formula 3 , F may be in a form connected to another oxypropylene group of Formula 3.
- n is determined such that the average molecular weight of the [OCH 2 CH 2 ]n site in the peptide conjugate, such as a number average molecular weight, is 1 to 100 kDa, or 1 to 20 kDa or 10 kDa. may be, but is not limited thereto.
- the moiety at which X is connected to the succinimide ring of Formula 2 or the succinimide ring of Formula 2 may be a sulfur atom of the C-terminal cysteine of X.
- the site at which X is connected to the oxypropylene group of Formula 3 or the oxypropylene group of Formula 3 may be a sulfur atom of the C-terminal cysteine of X.
- the site connected to the oxypropylene group of Formula 2 or Formula 3 in F is not particularly limited.
- the moiety of F connected to the oxypropylene group may be an N-terminal nitrogen or a nitrogen atom of an F internal moiety (eg, epsilon nitrogen of lysine).
- the moiety where F is connected to the oxypropylene group of Formula 2 or Formula 3 may be the N-terminal proline of F, but is not limited thereto.
- the insulin-secreting peptide, GLP-2, or a long-acting conjugate thereof includes all forms of itself, a salt (eg, a pharmaceutically acceptable salt) thereof, or a solvate thereof.
- insulin-secreting peptide GLP-2, or a long-acting conjugate thereof may be in any pharmaceutically acceptable form.
- the type of the salt is not particularly limited. However, it is preferable that the form is safe and effective for an individual, such as a mammal, but is not particularly limited thereto.
- salts derived from pharmaceutically acceptable inorganic acids, organic acids, or bases include hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, perchloric acid, fumaric acid, maleic acid, phosphoric acid, glycolic acid, lactic acid, salicylic acid, succinic acid, toluene-p-sulfonic acid, tartaric acid, acetic acid, citric acid, methanesulfonic acid, formic acid , benzoic acid, malonic acid, naphthalene-2-sulfonic acid, benzenesulfonic acid, and the like.
- Salts derived from suitable bases may include alkali metals such as sodium and potassium, alkaline earth metals such as magnesium, and ammonium.
- solvate refers to a compound in which the peptide, compound, or salt thereof according to the present invention forms a complex with a solvent molecule.
- the native insulin-secreting peptide and the modified insulin-secreting peptide of the present invention, GLP-2 can be synthesized through a solid phase synthesis method, can also be produced by a recombinant method, and can be commercially commissioned.
- the combination, pharmaceutical composition, or pharmaceutical kit of the present invention comprises
- (i) comprises an insulin-secreting peptide and GLP-2;
- an insulin-secreting peptide long-acting conjugate to which a biocompatible substance capable of increasing the in vivo half-life is bound; and a GLP-2 long-acting conjugate to which a biocompatible material capable of increasing the in vivo half-life is bound.
- the combination, pharmaceutical composition or pharmaceutical kit of the present invention can be used for the prevention, improvement or treatment of short bowel syndrome.
- prevention refers to any action that inhibits or delays the onset of a target disease, such as short bowel syndrome, by administration of a combination or composition comprising an insulin-secreting peptide and GLP-2
- treatment refers to any action of insulin It refers to any action in which the symptoms of a target disease, such as short bowel syndrome, are improved or beneficial by administration of a combination or composition comprising a secreted peptide and GLP-2.
- improved means any action that at least reduces the severity of a parameter, eg, a symptom, associated with the condition to be treated by administration of a combination or composition of the present invention.
- the term "administration" means introducing a predetermined substance to a patient by any suitable method, and the route of administration of the composition is not particularly limited thereto, but any general route through which the composition can reach an in vivo target It can be administered through, for example, intraperitoneal administration, intravenous administration, intramuscular administration, subcutaneous administration, intradermal administration, oral administration, topical administration, intranasal administration, intrapulmonary administration, rectal administration, etc. can be .
- the insulin-secreting peptide and GLP-2 may be used in combination to prevent or treat short bowel syndrome.
- SBS short bowel syndrome
- the combination or composition according to the present invention can prevent, ameliorate or treat short bowel syndrome by causing one or more of weight gain, increase in small intestine length, decrease in gastrointestinal motility, and increase in nutrient absorption when administered to a subject.
- the present invention is not limited thereto.
- the pharmaceutical composition of the present invention may further include a pharmaceutically acceptable carrier, excipient or diluent.
- a pharmaceutically acceptable carrier excipient or diluent.
- Such pharmaceutically acceptable carriers, excipients, or diluents may be non-naturally occurring.
- the term "pharmaceutically acceptable” means a sufficient amount to exhibit a therapeutic effect and does not cause side effects, and the type of disease, the patient's age, weight, health, sex, and the patient's sensitivity to the drug , administration route, administration method, frequency of administration, treatment period, combination or drugs used at the same time can be easily determined by those skilled in the art according to factors well known in the medical field.
- the pharmaceutical composition of the present invention may further include a pharmaceutically acceptable excipient.
- the excipient is not particularly limited thereto, but in the case of oral administration, a binder, a lubricant, a disintegrant, a solubilizer, a dispersing agent, a stabilizer, a suspending agent, a dye, a flavoring agent, etc. may be used, and in the case of an injection, a buffer, a preservative, An analgesic agent, a solubilizer, an isotonic agent, a stabilizer, etc. can be mixed and used, and in the case of topical administration, a base, excipient, lubricant, preservative, etc. can be used.
- the formulation of the composition of the present invention can be prepared in various ways by mixing with the pharmaceutically acceptable excipients as described above.
- it may be prepared in the form of tablets, troches, capsules, elixirs, suspensions, syrups, wafers, and the like, and in the case of injections, it may be prepared in the form of unit dose ampoules or multiple doses.
- it can be formulated as a solution, suspension, tablet, pill, capsule, sustained release formulation, and the like.
- suitable carriers, excipients and diluents for formulation include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, Microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, or mineral oil may be used.
- it may further include a filler, an anti-aggregating agent, a lubricant, a wetting agent, a flavoring agent, a preservative, and the like.
- the pharmaceutical composition of the present invention is any one selected from the group consisting of tablets, pills, powders, granules, capsules, suspensions, internal solutions, emulsions, syrups, sterile aqueous solutions, non-aqueous solvents, freeze-dried preparations and suppositories may have the form of
- composition is formulated in a dosage form suitable for administration in a patient's body according to a conventional method in the pharmaceutical field, specifically, a formulation useful for administration of a protein drug, and administration commonly used in the art.
- the conjugate can be used by mixing with various pharmaceutically acceptable carriers such as physiological saline or organic solvents, and carbohydrates such as glucose, sucrose or dextran, ascorbic acid (ascorbic acid) to increase stability or absorption acid) or antioxidants such as glutathione, chelating agents, low molecular weight proteins or other stabilizers, etc. may be used as agents.
- various pharmaceutically acceptable carriers such as physiological saline or organic solvents, and carbohydrates such as glucose, sucrose or dextran, ascorbic acid (ascorbic acid) to increase stability or absorption acid) or antioxidants such as glutathione, chelating agents, low molecular weight proteins or other stabilizers, etc.
- the dosage and frequency of administration of the pharmaceutical composition of the present invention is determined according to the type of drug as the active ingredient, together with several related factors such as the disease to be treated, the route of administration, the age, sex and weight of the patient, and the severity of the disease. .
- the composition of the present invention may include the peptide or a long-acting conjugate comprising the same in a pharmaceutically effective amount, but is not limited thereto.
- the inclusion of the insulin-secreting peptide or GLP-2 in a pharmaceutically effective amount means the degree to which a desired pharmacological activity can be obtained due to the insulin-secreting peptide or GLP-2, and no toxicity or side effects do not occur in the administered subject, or It may mean a pharmaceutically acceptable level as an insignificant level, but is not limited thereto. Such a pharmaceutically effective amount may be determined by comprehensively considering the number of administration, patient, formulation, and the like.
- the pharmaceutical composition of the present invention may contain the component (active ingredient) in an amount of 0.01 to 99% by weight to volume.
- the total effective amount of the composition of the present invention may be administered to a patient as a single dose, or may be administered by a fractionated treatment protocol in which multiple doses are administered for a long period of time.
- the pharmaceutical composition of the present invention may vary the content of the active ingredient according to the severity of the disease.
- the preferred total dose of the peptide or conjugate of the present invention may be about 0.0001 mg to 500 mg per 1 kg of the patient's body weight per day, but is not limited thereto.
- the dosage of the conjugate is determined by considering various factors such as the age, weight, health status, sex, severity of disease, diet and excretion rate of the patient, as well as the administration route and number of treatments of the pharmaceutical composition, and the effective dosage for the patient is determined.
- the pharmaceutical composition according to the present invention is not particularly limited in its formulation, administration route and administration method as long as the effect of the present invention is exhibited.
- the pharmaceutical composition of the present invention has excellent in vivo persistence and potency, and can significantly reduce the number and frequency of administration of the pharmaceutical preparation of the present invention, but is not limited thereto.
- Another aspect embodying the present invention provides a pharmaceutical composition for preventing, improving or treating short bowel syndrome, comprising the insulin-secreting peptide, characterized in that it is used in combination with GLP-2.
- the insulin-secreting peptide, GLP-2, prevention, treatment, improvement, combination, short bowel syndrome and pharmaceutical composition are as described above.
- Another embodiment of the present invention provides a food composition for preventing or improving short bowel syndrome containing an insulin-secreting peptide, wherein the insulin-secreting peptide is administered in combination with GLP-2.
- the insulin-secreting peptide, GLP-2, prevention, improvement, combination, and short bowel syndrome are the same as described above.
- the food composition may be used as a health functional food.
- the composition of the present invention is used as a food additive, the insulin-secreting peptide, GLP-2, a long-acting conjugate comprising the same, or a combination thereof can be added as it is or used with other foods or food ingredients, and can be used in a conventional method. can be used appropriately.
- the mixing amount of the active ingredient may be appropriately determined according to the purpose of use (prevention, health or therapeutic treatment).
- the term "health functional food” refers to a food manufactured and processed by extracting, concentrating, refining, mixing, etc., a specific ingredient as a raw material or a specific ingredient contained in a food raw material for the purpose of health supplementation, It refers to a food designed and processed to sufficiently exert biological control functions such as biological defense, regulation of biological rhythm, prevention and recovery of disease, etc., by the above ingredients, and the composition for health food is used for prevention of diseases and prevention of diseases. It can perform functions related to recovery, etc.
- Another aspect embodying the present invention provides a method for preventing, improving or treating short bowel syndrome, comprising administering an insulin-secreting peptide and GLP-2 to an individual in need thereof.
- it may be a method for preventing, improving or treating short bowel syndrome, comprising administering and/or using the combination, pharmaceutical composition, or pharmaceutical kit of the present invention to an individual in need thereof.
- compositions containing a pharmaceutically effective amount of an insulin-secreting peptide, and a composition containing a pharmaceutically effective amount of GLP-2 comprising the step of co-administering and/or using the composition to an individual in need thereof
- a method for preventing, improving or treating short bowel syndrome comprising the step of co-administering and/or using the composition to an individual in need thereof
- the insulin-secreting peptide, GLP-2, prevention, treatment, improvement, short bowel syndrome, combination, combination, pharmaceutical composition and pharmaceutical kit are as described above.
- the subject is a subject suspected of short bowel syndrome
- the subject suspected of short bowel syndrome refers to mammals including rats, livestock, etc. including humans that have or may develop the disease, but with the composition of the present invention. Treatable subjects are included without limitation.
- the composition of the present invention to a subject suspected of short bowel syndrome disease, the subject can be efficiently treated.
- Short bowel syndrome is the same as described above.
- the method of the present invention may comprise administering a combination or pharmaceutical composition comprising an insulin secreting peptide and GLP-2 in a pharmaceutically effective amount.
- the method according to the present invention may include, but is not limited to, administering the insulin-secreting peptide and GLP-2 as a single agent, or administering the separate agents simultaneously, separately, sequentially or in reverse order.
- a suitable total daily amount may be determined by a treating physician within the scope of sound medical judgment, and may be administered once or divided into several doses.
- a specific therapeutically effective amount for a particular patient depends on the type and extent of the response to be achieved, the specific composition, including whether other agents are used, if necessary, the specific composition, the patient's age, weight, general health, It is preferable to apply differently depending on various factors including sex and diet, administration time, administration route and secretion rate of the composition, treatment period, drugs used together or concurrently with a specific composition, and similar factors well known in the pharmaceutical field.
- Another aspect embodying the present invention is the use of the combination, pharmaceutical composition, or pharmaceutical kit for the prevention, improvement or treatment of short bowel syndrome, and/or for the preparation of a medicament for the prevention or treatment of short bowel syndrome. is the use
- CA-Exendin4 N-[2-(1H-Imidazol-5-yl)acetyl]-Exendin4, Hanmi Fine Chemicals, Korea) having an amine group at the 27th lysine residue in the peptide and an aldehyde group at both ends
- a peptide conjugate (mono-PEGylated CA-Exendin-4) PEGylated through a covalent bond between polyethylene glycol (3.4 kDa, ALD(2) PEG, Hanmi Fine Chemical, Korea) was prepared.
- the molar ratio of CA-Exendin-4: ALD(2) PEG is 1:5 to 1:15
- the concentration of CA-Exendin-4 is 6 to 12 mg/ml
- at 4 to 10°C to room temperature about It was made to react for 4 to 12 hours.
- the reaction was carried out in 0.1 M HEPES pH 7.0 to 8.5, about 45% isopropanol, and sodium cyanoborohydride (NaCNBH 3 ) at a concentration of 2 to 50 mM was added and reacted.
- the reaction solution was purified using a Source 15S (Cytiva, USA) column using a buffer containing sodium citrate (pH 2.0 to 3.5), about 45% ethanol, and a potassium chloride concentration gradient.
- CA-Exendin-4-PEG-Fc conjugate In order to prepare a CA-Exendin-4-PEG-Fc conjugate, an immunoglobulin Fc fragment was added to the mono-pegylated CA-Exendin-4 obtained in Example 1-1 to increase the total protein concentration to 10-50 mg/ ml, and then reacted for about 12 to 17 hours at 4 to 10 °C to room temperature. At this time, the reaction solution was 0.1 M potassium phosphate pH 5.5 to 8.5, and 2 to 50 mM sodium cyanoborohydride as a reducing agent was added. After completion of the reaction, the CA-Exendin-4-PEG-Fc conjugate in the reaction solution was purified using two types of hydrophobic bonding and anion exchange columns.
- Source 15Phenyl which is a hydrophobic binding column
- unreacted immunoglobulin Fc fragments were isolated and purified using Tris-HCl (pH 7.5) buffer and NaCl concentration gradient
- Source 15Q (Cytiva, USA)
- the CA-Exendin-4-PEG-Fc conjugate was isolated and purified by removing the over-reacted impurities using a Tris-HCl (pH 7.5) buffer and a NaCl concentration gradient.
- the GLP-2 derivative CA GLP-2 RK of SEQ ID NO: 4 in Table 1 is modified polyethylene glycol ALD (2) PEG (hydrogens at both ends are substituted with propionaldehyde groups (3-oxopropyl groups), respectively, and ethylene glycol repeating units For pegylation with modified polyethylene glycol having a moiety formula weight of 3.4 kDa, NOF, Japan), the molar ratio of the GLP-2 derivative and ALD(2) PEG was 1:5 to 1:20, GLP-2 The concentration of the derivative was 5 to 10 mg/ml, and the reaction was carried out at 2 to 8° C. for 4 to 16 hours.
- reaction was made in 20 mM HEPES (HEPES) pH 7.5 and ethanol, and 20 mM sodium cyanoborohydride as a reducing agent was added to the reaction.
- the reaction solution was a monopegylated GLP-2 derivative was purified using a Source 15S (GE, USA) column using a buffer solution containing sodium citrate pH 2.0, ethanol, and a concentration gradient of potassium chloride.
- the molar ratio of the purified monopegylated GLP-2 derivative to the immunoglobulin Fc fragment is 1:2 to 1:6, and the total protein concentration is 30 to 35 mg/mL and heated at 2 to 8°C.
- the reaction was carried out for 12 to 20 hours.
- 20 mM sodium cyanoborohydride as a reducing agent was added to the reaction solution in 100 mM potassium phosphate buffer (pH 6.0) and isopropanol.
- the reaction solution was applied to a Source 15Q (GE, USA) column using a bis-Tris pH 6.5 buffer and a sodium chloride concentration gradient, and a concentration gradient of ammonium sulfate and sodium citrate pH 5.0 to 5.2 was applied to Source 15 ISO (GE, USA), and a long-acting conjugate of the GLP-2 derivative, which is a conjugate in which the GLP-2 derivative is covalently linked to an immunoglobulin Fc fragment by a polyethylene glycol linker, was purified.
- Source 15Q GE, USA
- Example 3 Confirmation of increase in mouse body weight and small intestine length by co-administration of GLP-1 derivative long-acting conjugate and GLP-2 derivative long-acting conjugate
- mice were used to measure the effect of improving in vivo body weight and small intestine length following the co-administration of the GLP-1 derivative long-acting conjugate and the GLP-2 derivative long-acting conjugate. Specifically, 7-week-old male mice (C57BL/6) were divided into 5 mice per group as follows:
- GLP-1 derivative long-acting conjugate 0.039 mg/kg/Q2D
- GLP-1 derivative long-acting conjugate 0.039 mg/kg/Q2D, 2 weeks
- G3 group administered with GLP-2 derivative long-acting conjugate (0.889 mg/kg/Q2D) (GLP-2 derivative long-acting conjugate 0.889 mg/kg/Q2D, 2 weeks);
- GLP-1 derivative long-acting conjugate 0.039 mg/kg/Q2D
- GLP-2 derivative long-acting conjugate 0.889 mg/kg/Q2D
- 2 weeks GLP-1 derivative long-acting conjugate 0.039 mg/ kg/Q2D + GLP-2 derivative long-acting conjugate 0.889 mg/kg/Q2D
- the numerical value expressed as the dose of the GLP-1 derivative long-acting conjugate or the GLP-2 derivative long-acting conjugate is the polyethylene glycol linker site in the total mass of the GLP-1 derivative long-acting conjugate or GLP-2 derivative long-acting conjugate used. It is a numerical value excluding the mass of , that is, a numerical value expressed based on the sum of the masses of only the polypeptide regions.
- mice The weight of the mice was observed while repeating administration for 2 weeks (D0 to D14: the first day the drug was administered is designated as day 0). Thereafter, the length of the small intestine was measured through an autopsy at D14.
- Example 4 Decreased gastrointestinal motility by co-administration of a GLP-1 derivative long-acting conjugate and a GLP-2 derivative long-acting conjugate
- mice were used to measure the effect of co-administration of the GLP-1 derivative long-acting conjugate and the GLP-2 derivative long-acting conjugate to reduce gastrointestinal motility in vivo .
- 7-week-old male mice (C57BL/6) were divided into 6 mice per group as follows:
- GLP-1 derivative long-acting conjugate (0.136 mg/kg) (GLP-1 derivative long-acting conjugate 0.136 mg/kg);
- GLP-1 derivative long-acting conjugate (0.136 mg/kg) and GLP-2 derivative long-acting conjugate (3.111 mg/kg) administered group (GLP-1 derivative long-acting conjugate 0.136 mg/kg + GLP-2) Derivative long-acting conjugate 3.111 mg/kg).
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
Claims (22)
- 약학적 유효량의 인슐린 분비 펩타이드를 함유하는 단장증후군(short bowel syndrome)의 예방 또는 치료를 위한 약학적 조성물로서,상기 약학적 조성물은 글루카곤 유사 펩타이드-2(Glucagon-like peptide-2, GLP-2)와 병용 투여되는 것을 특징으로 하는 약학적 조성물.
- 약학적 유효량의 GLP-2를 함유하는 단장증후군의 예방 또는 치료를 위한 약학적 조성물로서,상기 약학적 조성물은 인슐린 분비 펩타이드와 병용 투여되는 것을 특징으로 하는 약학적 조성물.
- 제1항 또는 제2항에 있어서, 상기 인슐린 분비 펩타이드는 글루카곤 유사 펩타이드-1(Glucagon-like peptide-1, GLP-1), 엑센딘-3, 엑센딘-4, 이들의 작용제, 유도체, 단편, 변이체, 및 이들의 조합으로 구성되는 군으로부터 선택되는 약학적 조성물.
- 제1항 또는 제2항에 있어서, 상기 인슐린 분비 펩타이드는 인슐린 분비 펩타이드의 N-말단 히스티딘 잔기가 이미다조아세틸데스히스티딘, 데스아미노히스티딘, β-히드록시이미다조프로피온일데스히스티딘, N-디메틸히스티딘, 또는 β-카복시이미다조프로피온일데스히스티딘으로 치환된 인슐린 분비 펩타이드 유도체인, 약학적 조성물.
- 제1항 또는 제2항에 있어서, 상기 인슐린 분비 펩타이드는 천연형 엑센딘-4, 엑센딘-4의 N-말단 첫 번째 아미노산인 히스티딘 잔기의 알파 탄소 및 알파 탄소에 결합된 N-말단 아미노기가 제거된 엑센딘-4 유도체, 엑센딘-4의 N-말단 아미노기가 제거된 엑센딘-4 유도체, 엑센딘-4의 N-말단 아미노기가 하이드록실기로 치환된 엑센딘-4 유도체, 엑센딘-4의 N-말단 아미노기가 2개의 메틸기로 수식된 엑센딘-4 유도체, 엑센딘-4의 N-말단 아미노기가 카복실기로 치환된 엑센딘-4 유도체, 엑센딘-4의 열두 번째 아미노산(라이신)이 세린으로 치환된 엑센딘-4 유도체, 또는 엑센딘-4의 열두 번째 아미노산(라이신)이 아르지닌으로 치환된 엑센딘-4 유도체인 약학적 조성물.
- 제1항 또는 제2항에 있어서, 상기 GLP-2는 천연형 GLP-2 또는 GLP-2 유도체인, 약학적 조성물.
- 제6항에 있어서, 상기 GLP-2 유도체는 천연형 GLP-2 서열에서 적어도 하나의 아미노산에 치환(substitution), 추가(addition), 제거(deletion), 수식(modification) 및 이들의 조합으로 이루어지는 군에서 선택된 변형이 일어난 GLP-2 유도체인 약학적 조성물.
- 제6항에 있어서, 상기 GLP-2 유도체는 서열번호 1에서 1번, 2번, 30번 및 33번의 아미노산 중 적어도 하나의 아미노산에 변형이 일어난 것인 약학적 조성물.
- 제6항에 있어서, 상기 GLP-2 유도체는 하기 일반식 1로 표시되는 아미노산 서열을 포함하는 약학적 조성물:[일반식 1]X1X2DGSFSDEMNTILDNLAARDFINWLIQTX30ITDX34 (서열번호 9)여기서,X1은 히스티딘, 이미다조아세틸데스히스티딘, 데스아미노히스티딘, β-히드록시이미다조프로피온일데스히스티딘, N-디메틸히스티딘, 또는 β-카복시이미다조프로피온일데스히스티딘이고;X2는 알라닌, 글라이신, 또는 Aib(2-aminoisobutyric acid)이며;X30은 라이신 또는 아르지닌이고;X34는 부존재하거나, 라이신, 아르지닌, 글루타민, 히스티딘, 6-아지도라이신 또는 시스테인이고;다만, 일반식 1의 아미노산 서열 중에서 서열번호 1과 동일한 서열은 제외한다.
- 제9항에 있어서, 상기 GLP-2 유도체는(1) X1이 이미다조아세틸데스히스티딘이고, X2가 글라이신이고, X30이 라이신이고, X34가 시스테인이거나,(2) X1이 이미다조아세틸데스히스티딘이고, X2가 글라이신이고, X30이 라이신이고, X34가 라이신이거나,(3) X1이 이미다조아세틸데스히스티딘이고, X2가 글라이신이고, X30이 아르지닌이고, X34가 라이신이거나,(4) X1이 이미다조아세틸데스히스티딘이고, X2가 글라이신이고, X30이 라이신이고, X34가 6-아지도라이신이거나,(5) X1이 이미다조아세틸데스히스티딘이고, X2가 글라이신이고, X30이 아르지닌이고, X34가 시스테인이거나,(6) X1이 이미다조아세틸데스히스티딘이고, X2가 Aib이고, X30이 라이신이고, X34가 시스테인이거나, 또는(7) X1이 히스티딘이고, X2가 Aib이고, X30이 라이신이고, X34가 시스테인인 약학적 조성물.
- 제6항에 있어서, 상기 GLP-2 유도체는 하기 일반식 2로 표시되는 아미노산 서열을 포함하는 약학적 조성물:[일반식 2]X1X2DGSFSDEMNTILDNLAARDFINWLIQTX30ITDX34 (서열번호 10)여기서,X1은 히스티딘, 이미다조아세틸데스히스티딘, 데스아미노히스티딘, β-히드록시이미다조프로피온일데스히스티딘, N-디메틸히스티딘, 또는 β-카복시이미다조프로피온일데스히스티딘이고;X2는 알라닌, 글라이신, 또는 Aib(2-aminoisobutyric acid)이며;X30은 라이신 또는 아르지닌이고;X34는 하나 이상의 임의의 아미노산 또는 변형이 일어난 하나 이상의 임의의 아미노산이고;다만, 일반식 2의 아미노산 서열 중에서 서열번호 1과 동일한 서열은 제외한다.
- 제6항에 있어서, 상기 GLP-2 유도체는 서열번호 2 내지 8로 이루어진 군으로부터 선택된 아미노산 서열의 펩타이드인 약학적 조성물.
- 제1항 또는 제2항에 있어서, 상기 조성물은 개체에 투여 시 체중 증가, 소장 길이 증가, 위장관 운동성 감소, 및 영양분 흡수 증가 중 하나 이상을 야기하는 약학적 조성물.
- 제1항 또는 제2항에 있어서, 상기 인슐린 분비 펩타이드 및 GLP-2는 이의 C-말단이 변형되지 않았거나 아미드화된 약학적 조성물.
- 제1항 또는 제2항에 있어서,(i) 상기 인슐린 분비 펩타이드는 이의 생체 내 반감기를 증가시킬 수 있는 생체적합성 물질이 결합된, 지속형 결합체의 형태이거나,(ii) 상기 GLP-2는 이의 생체 내 반감기를 증가시킬 수 있는 생체적합성 물질이 결합된, 지속형 결합체의 형태이거나,(iii) 상기 인슐린 분비 펩타이드 및 GLP-2 각각은 이들의 생체 내 반감기를 증가시킬 수 있는 생체적합성 물질이 결합된, 지속형 결합체의 형태인 약학적 조성물.
- 제15항에 있어서, 상기 결합체는 하기 화학식 1로 표시되는 약학적 조성물:[화학식 1]X - La - F여기서,X는 인슐린 분비 펩타이드 또는 GLP-2이고;L은, 에틸렌글리콜 반복 단위를 함유하는 링커이며;a는, 0 또는 자연수이며, 다만 a가 2 이상일 때, 각각의 L은 서로 독립적이고;F는, 면역글로불린 Fc 영역이며;상기 "-"는 공유결합임.
- 제16항에 있어서, 상기 면역글로불린 Fc 영역은 비당쇄화된 IgG4 Fc 영역인 약학적 조성물.
- 제16항에 있어서, 상기 F는 두 개의 폴리펩타이드 사슬로 이루어진 이합체이며, L의 한 말단이 상기 두 개의 폴리펩타이드 사슬 중 하나의 폴리펩티드 사슬에만 연결되어 있는 약학적 조성물.
- 제16항에 있어서, 상기 L은 폴리에틸렌글리콜인 약학적 조성물.
- 제16항에 있어서, 상기 L 내의 에틸렌글리콜 반복 단위 부위의 화학식량은 1 내지 100 kDa 범위에 있는 약학적 조성물.
- 제1항 또는 제2항에 있어서, 상기 조성물은 약학적으로 허용가능한 담체, 부형제 또는 희석제를 추가로 포함하는 약학적 조성물.
- 제1항 또는 제2항에 있어서, 상기 인슐린 분비 펩타이드를 함유하는 조성물은 GLP-2를 함유하는 조성물과 동시, 순차적 또는 역순으로 병용 투여되는 것을 특징으로 하는 약학적 조성물.
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202180094229.4A CN116940370A (zh) | 2020-12-24 | 2021-12-24 | 用于预防或治疗短肠综合征的促胰岛素肽和glp-2的组合疗法 |
CA3201916A CA3201916A1 (en) | 2020-12-24 | 2021-12-24 | Combination therapy of insulinotropic peptide and glp-2, for preventing or treating short bowel syndrome |
EP21911617.5A EP4302776A1 (en) | 2020-12-24 | 2021-12-24 | Combination therapy of insulinotropic peptide and glp-2, for preventing or treating short bowel syndrome |
AU2021409610A AU2021409610A1 (en) | 2020-12-24 | 2021-12-24 | Combination therapy of insulinotropic peptide and glp-2, for preventing or treating short bowel syndrome |
IL303624A IL303624A (en) | 2020-12-24 | 2021-12-24 | Combined treatment of insulinotropic peptide and GLP-2, for the prevention or treatment of short bowel syndrome |
JP2023537538A JP2024503242A (ja) | 2020-12-24 | 2021-12-24 | 短腸症候群の予防又は治療のためのインスリン分泌ペプチドとglp-2の併用療法 |
MX2023007498A MX2023007498A (es) | 2020-12-24 | 2021-12-24 | Terapia de combinacion del peptido insulinotropico y glp-2, para prevenir o tratar el sindrome del intestino corto. |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2020-0183440 | 2020-12-24 | ||
KR20200183440 | 2020-12-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022139552A1 true WO2022139552A1 (ko) | 2022-06-30 |
Family
ID=82158214
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2021/019854 WO2022139552A1 (ko) | 2020-12-24 | 2021-12-24 | 단장증후군의 예방 또는 치료를 위한 인슐린 분비 펩타이드 및 glp-2의 병용 요법 |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP4302776A1 (ko) |
JP (1) | JP2024503242A (ko) |
KR (1) | KR20220092446A (ko) |
CN (1) | CN116940370A (ko) |
AU (1) | AU2021409610A1 (ko) |
CA (1) | CA3201916A1 (ko) |
IL (1) | IL303624A (ko) |
MX (1) | MX2023007498A (ko) |
WO (1) | WO2022139552A1 (ko) |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5424286A (en) | 1993-05-24 | 1995-06-13 | Eng; John | Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same |
WO1996032478A1 (en) | 1995-04-14 | 1996-10-17 | Genentech, Inc. | Altered polypeptides with increased half-life |
WO1997034631A1 (en) | 1996-03-18 | 1997-09-25 | Board Of Regents, The University Of Texas System | Immunoglobin-like domains with increased half lives |
JP2011506442A (ja) * | 2007-12-11 | 2011-03-03 | コンジュケム バイオテクノロジーズ インコーポレイテッド | インスリン分泌性ペプチド結合体の製剤 |
KR20110110174A (ko) * | 2008-12-19 | 2011-10-06 | 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 | 아미드 기반 글루카곤 슈퍼패밀리 펩티드 프로드럭 |
JP2014058528A (ja) * | 2006-08-17 | 2014-04-03 | Amylin Pharmaceuticals Llc | 選択可能な特性を持つdpp−iv耐性gipハイブリッドポリペプチド |
KR20190037181A (ko) | 2017-09-28 | 2019-04-05 | 한미약품 주식회사 | 글루카곤 유사 펩타이드-2(glp-2) 유도체의 지속형 결합체 |
-
2021
- 2021-12-24 JP JP2023537538A patent/JP2024503242A/ja active Pending
- 2021-12-24 EP EP21911617.5A patent/EP4302776A1/en active Pending
- 2021-12-24 AU AU2021409610A patent/AU2021409610A1/en active Pending
- 2021-12-24 KR KR1020210187452A patent/KR20220092446A/ko unknown
- 2021-12-24 CN CN202180094229.4A patent/CN116940370A/zh active Pending
- 2021-12-24 IL IL303624A patent/IL303624A/en unknown
- 2021-12-24 MX MX2023007498A patent/MX2023007498A/es unknown
- 2021-12-24 WO PCT/KR2021/019854 patent/WO2022139552A1/ko active Application Filing
- 2021-12-24 CA CA3201916A patent/CA3201916A1/en active Pending
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5424286A (en) | 1993-05-24 | 1995-06-13 | Eng; John | Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same |
WO1996032478A1 (en) | 1995-04-14 | 1996-10-17 | Genentech, Inc. | Altered polypeptides with increased half-life |
WO1997034631A1 (en) | 1996-03-18 | 1997-09-25 | Board Of Regents, The University Of Texas System | Immunoglobin-like domains with increased half lives |
JP2014058528A (ja) * | 2006-08-17 | 2014-04-03 | Amylin Pharmaceuticals Llc | 選択可能な特性を持つdpp−iv耐性gipハイブリッドポリペプチド |
JP2011506442A (ja) * | 2007-12-11 | 2011-03-03 | コンジュケム バイオテクノロジーズ インコーポレイテッド | インスリン分泌性ペプチド結合体の製剤 |
KR20110110174A (ko) * | 2008-12-19 | 2011-10-06 | 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 | 아미드 기반 글루카곤 슈퍼패밀리 펩티드 프로드럭 |
KR20190037181A (ko) | 2017-09-28 | 2019-04-05 | 한미약품 주식회사 | 글루카곤 유사 펩타이드-2(glp-2) 유도체의 지속형 결합체 |
Non-Patent Citations (2)
Title |
---|
K.B. MADSEN, C. ASKOV-HANSEN, R.M. NAIMI, C.F. BRANDT, B. HARTMANN, J.J. HOLST, P.B. MORTENSEN, P.B. JEPPESEN: "Acute effects of continuous infusions of glucagon-like peptide (GLP)-1, GLP-2 and the combination (GLP-1+GLP-2) on intestinal absorption in short bowel syndrome (SBS) patients. A placebo-controlled study", REGULATORY PEPTIDES, ELSEVIER, vol. 184, 1 June 2013 (2013-06-01), pages 30 - 39, XP055183143, ISSN: 01670115, DOI: 10.1016/j.regpep.2013.03.025 * |
LJUNGMANN K. ET AL., AM. J. PHYSIOL. GASTROINTEST LIVER PHYSIOL., vol. 281, no. 3, 2001, pages G779 - 85 |
Also Published As
Publication number | Publication date |
---|---|
JP2024503242A (ja) | 2024-01-25 |
IL303624A (en) | 2023-08-01 |
AU2021409610A1 (en) | 2023-07-06 |
EP4302776A1 (en) | 2024-01-10 |
CN116940370A (zh) | 2023-10-24 |
KR20220092446A (ko) | 2022-07-01 |
MX2023007498A (es) | 2023-07-05 |
CA3201916A1 (en) | 2022-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2017116205A1 (ko) | 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체의 지속형 결합체 | |
AU2016287209B2 (en) | Glucagon derivative and a composition comprising a long acting conjugate of the same | |
WO2012173422A1 (en) | A conjugate comprising oxyntomodulin and an immunoglobulin fragment, and use thereof | |
WO2018004283A2 (ko) | 글루카곤 유도체, 이의 결합체, 및 이를 포함하는 조성물, 및 이의 치료적 용도 | |
WO2017052321A1 (ko) | 다수의 생리활성 폴리펩타이드 및 면역글로불린 Fc 영역을 포함하는, 단백질 결합체 | |
WO2015152618A1 (ko) | 면역글로불린 fc 단편 결합을 이용한 단백질 및 펩타이드의 용해도를 개선시키는 방법 | |
WO2019066586A1 (ko) | 글루카곤 유사 펩타이드-2(glp-2) 유도체의 지속형 결합체 | |
WO2020130749A1 (ko) | 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체 및 인슐린을 포함하는 약학 조성물 | |
WO2017155288A1 (ko) | 폴리에틸렌 글리콜 유도체 및 이의 용도 | |
WO2017116207A1 (ko) | Fgf21 아날로그, fgf21 결합체, 및 이의 용도 | |
WO2018174668A2 (ko) | 인슐린 수용체와의 결합력이 감소된 인슐린 아날로그의 결합체 및 이의 용도 | |
WO2022211537A1 (ko) | 신규한 면역 활성 인터루킨 2 아날로그 결합체 및 이의 제조 방법 | |
WO2022015082A1 (ko) | 글루카곤 유도체 또는 이의 결합체의 간질환에 대한 치료적 용도 | |
WO2020071865A1 (ko) | 글루카곤 및 이를 포함하는 조합물의 치료학적 용도 | |
WO2021201654A1 (ko) | Glp-2 유도체 또는 이의 지속형 결합체를 포함하는 방사선요법, 화학요법, 또는 이들의 조합으로 유발된 점막염의 예방 또는 치료용 약학적 조성물 | |
WO2021066600A1 (ko) | 글루카곤, 및 glp-1 수용체 및 gip 수용체 이중 작용제를 포함하는 조성물 및 이의 치료학적 용도 | |
WO2023106845A1 (ko) | 신규한 아디포넥틴 아날로그 및 결합체 | |
WO2021235913A1 (ko) | Glp-2의 지속형 결합체의 액상 제제 | |
WO2021133087A1 (ko) | Glp-2 또는 이의 결합체를 포함하는 골 대사성 질환에 대한 예방 또는 치료용 약학적 조성물 | |
WO2021235907A1 (ko) | 글루카곤 유도체의 지속형 결합체의 액상 제제 | |
WO2022139552A1 (ko) | 단장증후군의 예방 또는 치료를 위한 인슐린 분비 펩타이드 및 glp-2의 병용 요법 | |
WO2022015115A1 (ko) | 3중 작용성 지속형 결합체 또는 3중 작용제를 포함하는 조합물의 치료학적 용도 | |
WO2021215801A1 (ko) | 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체 또는 이의 결합체를 포함하는 고지혈증 예방 또는 치료용 약학적 조성물 및 예방 또는 치료 방법 | |
WO2020214013A1 (ko) | 글루카곤, glp-1 및 gip 수용체 모두에 활성을 갖는 삼중 활성체 또는 이의 결합체의 고지혈증에 대한 치료적 용도 | |
WO2023204556A1 (ko) | 장질환의 예방 또는 치료를 위한 GLP-2와, 인슐린 분비 펩타이드, TNFα 억제제, 또는 이 둘 모두의 병용 요법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21911617 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3201916 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2023537538 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2023/007498 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 18269134 Country of ref document: US |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112023012413 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 2021409610 Country of ref document: AU Date of ref document: 20211224 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 112023012413 Country of ref document: BR Kind code of ref document: A2 Effective date: 20230621 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2023115737 Country of ref document: RU |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2021911617 Country of ref document: EP Effective date: 20230724 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202180094229.4 Country of ref document: CN |